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ABSTRACT 
 
MICHELLE CARIN DESIMONE: In Vitro and In Vivo Models to Assess Kidney 
Toxicity of Environmental Carcinogens 
(Under the direction of David W. Threadgill, Ph.D) 
 
The etiology of sporadic kidney cancer in humans is unclear. However, it 
is known that VHL tumor suppressor gene mutations are found in the majority of 
human renal tumors, even in the earliest stages, and play an important role in 
kidney cancer development. Evidence suggests that VHL may be a target for 
environmental carcinogens such as trichloroethylene (TCE), which is associated 
with a specific point mutation in the VHL gene. Co-exposures to elevated levels 
of TCE and inorganic arsenic through groundwater and dietary sources are 
frequently found in human populations and are thought to cause multiple organ 
toxicities. We hypothesize that there is a mechanistic link between environmental 
co-exposures to TCE- and arsenic-induced renal toxicity that can be elucidated 
using genetically engineered model systems. Here we have generated both an in 
vitro model system of the TCE-associated VHL mutation in embryonic stem cells, 
as well as a unique F3 mouse population derived from the cross between FVB/N-
-Abcb1a/1b-/-, a multi- drug resistant transporter knockout, and CAST/EiJ, a wild-
derived strain from a different subspecies of Mus musculus. We have employed 
these systems to elucidate the genetic and environmental components critical for 
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the development of renal cell carcinoma due to environmental co-exposures to 
TCE and arsenic. 
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INTRODUCTION 
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A. Genetic alterations in renal cancer  
1) Kidney cancer and the VHL tumor suppressor gene 
 The National Cancer Institute (NCI) estimates that over 54,000 new cases 
of kidney cancer were diagnosed in 2010, and that incidence increases 2% each 
year [1]. Despite this upward trend, the underlying cause of this continued 
increase is still unclear. Several risk factors have been identified that may 
predispose an individual to the development of renal cell carcinoma (RCC) that 
can be described as both environmental and genetic, including cigarette 
smoking, obesity, hypertension, and exposure to occupational chemicals [1]. 
Recent advances in our understanding of the genetics underlying the 
predisposition to RCC development enable certain susceptible individuals to be 
identified, despite their lack of common environmental risk factors. One example 
is the identification of the von-Hippel Lindau (VHL) tumor suppressor gene and 
the predisposition to develop VHL disease, a hereditary cancer syndrome 
predisposing to RCC as well as other tumors. VHL mutations and chromosomal 
deletions in the 3p13-p26 region, which harbors the VHL gene and other tumor 
suppressor genes, have been observed in both sporadic and hereditary clear cell 
RCC [2]. 
 VHL is considered the “gatekeeper” of human kidney cancer and plays an 
important role in the renal tumorigenesis [3]. As one would expect, many RCC 
tumors have mutations in the VHL gene that are not inherited, but are somatic in 
nature [2]. Clear cell renal cell carcinoma (ccRCC) is the most common form of 
sporadic kidney cancer and epidemiological studies have shown 60-80% of these 
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tumors have a VHL mutation [4]. The descriptive “clear cell” histological 
phenotype of these tumors results from the upregulation of glycolytic gene 
pathways. This increase in intracellular glycogen storage appears as clear 
spaces with hematoxylin and eosin histological staining [5]. Importantly, VHL 
protein (pVHL) functions as a substrate recognition protein in an E3-ubiquitin 
ligase complex which targets hypoxia-regulated transcription factors for 
degradation under normoxia, or normal oxygen conditions [6, 7]. Its ability to act 
in this complex is thought to be critical for its tumor suppressor function.  
2) Effects of mutations on pVHL function 
 To understand the consequence of VHL mutations, it is important to 
understand the functional role of VHL protein as a tumor suppressor. pVHL in 
association with Elongin B and C, Cullin 2, and RBX1, exerts its tumor 
suppressor function by acting as an E3-ubiquitin ligase complex (E3-complex) 
which targets hypoxia inducible transcription factors (HIFs) for degradation during 
normoxia (Figure 1.1) [6,7,8]. pVHL also maintains interactions with cell cycle 
regulatory proteins and transcriptional machinery [9,10]. The three major 
isoforms of HIFα, HIF1, HIF2 and HIF3, are conditionally regulated basic helix-
loop-helix transcription factors that share Per-Arnt-Sim (PAS) homology domains 
for dimerization with the aryl hydrocarbon nuclear translocator (ARNT or HIF1β) 
[11]. ARNT dimerization is considered necessary for HIF transactivation [12]. 
During low oxygen conditions, the failure of HIFs to be hydroxylated allows them 
to escape recognition and subsequent degradation, which allows them to bind to 
the hypoxia responsive elements (HRE) on target genes, some of which are 
 4 
involved in cellular glycolosis, growth factor production, and angiogenesis 
[7,8,11]. Mutations in VHL that disrupt this complex formation even partially can 
allow accumulation of nuclear HIF and transcriptional upregulation of hypoxia-
inducible genes under normoxic conditions [12, 13]. 
 HIF1 and HIF2 play dynamic roles in the progression of VHL-mediated 
renal tumorigenesis [7, 12, 13]. Both HIF1 and HIF2 are capable of binding the 
same HRE target genes, however, HIF2 is thought to bind with greater affinity to 
TGF-α, EPO, and VEGF [12]. While HIF1a is believed to be mainly responsible 
for the pro-glycolytic phenotype of ccRCC tumors, HIF2 stabilization is thought to 
contribute to the progression of tumor growth [12]. Molecular studies have shown 
that introduction of a stabilized HIF1a to RCC cells was not able to induce a 
tumorigenic phenotype [14]. However, when all three HIF isoforms are stabilized, 
tumorigenesis is restored. Further investigating this opposing role of HIF1 and 
HIF2, Kondo et al. developed a cell line with constitutive expression of stabile 
HIF2 in the presence of normal pVHL. Since pVHL and E3-complex was 
functional, HIF1 was suppressed while HIF2 remained stable. Stable expression 
of HIF2 alone was able to promote cell proliferation and tumorigenesis when 
grown as a xenograft [15]. This indicates that stabilization of HIF1, and 
importantly HIF2, during normoxic conditions is an important indicator of the 
pathogenesis of a particular VHL mutation. 
3) Modeling VHL mutations and their disease phenotypes 
 A strong genotype-phenotype correlation exists in the type of VHL 
mutation and the VHL disease phenotype observed in affected patients [16]. VHL 
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disease subtypes, and their representing mutations, have been classified based 
on their risk of developing pheochromocytoma and RCC (Table 1.1) [17]. For 
example, Type 1 mutations result in loss of pVHL expression that results in a 
high risk for renal cell carcinoma. Type 2 mutations are subdivided into 2A, 2B, 
and 2C. Type 2A mutations result in low risk for renal cell carcinoma while Type 
2B mutations result in high risk for renal cell carcinoma. The difference in renal 
cancer risk between type 2A and type 2B mutations can be inferred from its E3 
complex interactions and HIF regulation; 2A maintains E3 complex formation, 
while 2B does so partially [20]. Finally, 2C mutations do not result in any 
increased risk for renal cancer and maintain interactions with the E3-ubiquitin 
ligase complex [17]. Taken together, the risk for renal cell carcinoma associated 
with a particular VHL mutation can be inferred by molecularly classifying VHL 
mutations based on their ability to destabilize the E3-ubiquitin ligase complex 
formation and regulate HIFs. 
 Genetically engineered mouse embryonic stem cell systems have been a 
good model for determining the molecular alterations associated with particular 
VHL mutations [18, 19, 20, 21].  Vhl-/- embryonic stem cells are unable to regulate 
the hypoxia response pathway and have elevated levels of stabilized HIF1 and 
HIF2 under normal oxygen conditions [19, 20]. The predicted upregulation of 
HRE-responsive genes is also observed [19]. Introduction of the wild-type human 
pVHL into these cells, rescues the constitutive hypoxia signaling phenotype [20]. 
Cell lines harboring type 2A and type 2B VHL mutations, respectively named 
Y112H and R167Q, have been created and characterized for their ability to 
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interact and function with the E3-complex, as well as degrade HIF1 and HIF2 
under normoxic conditions [20]. Consistent with human data, the 2A mutant 
retains E3-complex formation, reflecting a low risk for RCC mutation, while the 
2B mutant shows disrupted complex formation due to a diminished interaction 
with Elongin C. However, it was observed that the 2B mutant still retains 
interactions with other complex members, Ringbox1 and Cullin-2, which explains 
its ability to partially ubiquitinate HIF1 during normoxia [21]. Interestingly, when 
these cells are grown in a teratoma model system, they are highly vascular due 
to aberrant HIF signaling [20]. These studies confirm that VHL mutations can be 
successfully modeled using genetically modified Vhl-/- ES cells to study the 
molecular effects of VHL mutations both in vivo and in vitro. 
B. Environmental exposures are associated with renal cancer 
1) Trichloroethylene exposure and VHL mutations 
 The VHL gene has been proposed to be a target of environmental 
carcinogens, such as trichloroethylene and N-nitrosodimethylamine [22, 23]. TCE 
is an aliphatic chlorinated hydrocarbon which was once used heavily as an 
industrial solvent, fire-retardant, and dry cleaning agent [24]. Due to the 
ubiquitous use and improper disposal of TCE from a multitude of industries over 
the past fifty years, TCE can be found in drinking water at low levels as well as 
concentrated at high levels in underground plumes [24]. TCE is considered a 
likely human carcinogen and national priority site compound by the 
Environmental Protection Agency, restricting its current use and disposal to 
reduce human exposure [25]. An epidemiological study by Brauch et al. 
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conducted at an industrial site in Germany, put forth evidence to suggest that 
occupational exposure to trichloroethylene resulted in a specific hotspot mutation 
in the VHL gene, and that multiplicity of VHL mutations in kidney tumors of this 
population positively correlated with their TCE exposure level [26]. The 
nucleotide 454 hotspot mutation resulted in a proline to serine amino acid change 
at codon 81, thus referred to as the P81S missense mutation. Despite the 
discovery of this specific hotspot mutation in VHL over a decade ago, the 
functional consequences of this mutation remain unknown. 
2) Bioactivation as a mechanism in TCE toxicity 
 The mechanisms governing kidney toxicity due to TCE exposure remain 
unclear due to its complex metabolism and extensive bioactivation (Figure 1.2). 
TCE is metabolized preferentially by the cytochrome p450 pathway to 
trichloroacetic acid (TCA), dichloroacetic acid (DCA) and trichloroethanol, and as 
a secondary pathway, TCE can also be conjugated to glutathione forming 
dichlorovinylglutathione (DCVG) [27]. DCVG, once in the blood stream, can be 
taken up into the proximal tubule epithelium of the kidney and is further 
hydrolyzed to dichlorovinylcysteine (DCVC). The metabolism of DCVC by beta-
lyase within the cytoplasm and mitochondria to a reactive thiol, is thought to be 
the reactive metabolite that contributes to the development of kidney toxicity [29]. 
However, the argument against a mutagenic mode of action is that this 
metabolite represents less than 0.1% of the total metabolite formation, and is 
unlikely to form at a concentration large enough to overwhelm DNA repair to 
result in mutagenesis of the VHL gene [27, 29].  
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 Further complicating our understanding is a discord between rodent 
species in the development of renal toxicity following TCE exposure. 
Carcinogenesis bioassays in Fisher 344 rats and B6C3F1 mice conducted at the 
National Toxicology Program have been inconclusive, with 3/50 rats and 0/50 
mice developing kidney tumors after a 2-year maximum tolerated dose bioassay 
[28]. Rodent genetics has been taken into consideration to find a more 
susceptible strain for testing. The Eker rat, a rat harboring a dominant mutant 
tuberous sclerosis (TSC2) allele, is more susceptible to renal carcinogens but did 
not show increased susceptibility to kidney tumor formation with TCE exposure 
[29]. In addition, haploinsufficient Vhl+/- mice have also been tested for increased 
susceptibility to known nephrotoxicants with the intention to later test the ability of 
TCE to mutate and inactivate the remaining Vhl allele if successful. However, no 
increase in susceptibility was observed [30]. Finally, conditional inactivation of 
Vhl without further challenge does not promote tumor formation, indicating that in 
mice, loss of Vhl is insufficient for the development of tumors [31]. The lack of 
RCC animal models of both VHL disease and trichloroethylene toxicity has 
thwarted an understanding of the mechanisms governing the role of TCE 
exposure in the development of renal carcinogenesis, as well as the possible role 
of VHL mutations in that development. 
3) Arsenic as a co-carcinogen 
There is increasing evidence that environmental exposure to inorganic arsenic 
can act as a co-carcinogen [32]. Inorganic arsenic is a naturally occurring 
element found in the Earth’s crust, thus it can be found in most water sources 
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and food items grown from arsenic-contaminated earth. It was discovered as one 
of the first known human carcinogens, causing tumors of the skin, lungs, bladder, 
kidney and liver [33]. Inorganic arsenic is metabolized to more toxic trivalent 
metabolites, dimethyl- and monomethyl- arsenic, which are excreted by the 
kidney into urine [34]. Inorganic arsenic is tightly monitored in public water 
systems with a federal EPA standard of 10ppb or 10µg/L being set. However, 
these limits are not well monitored in private wells or in food sources [35]. This 
has led to an increased exposure to certain populations where arsenic is 
abundant in soils, such as the “slate belt” of North Carolina, New Hampshire, 
India, Asia, Thailand and Mexico [36, 37]. A recent study has shown that arsenic 
is taken up and concentrated in rice at concentrations upwards of 50-450ug/kg 
rice [38], ten-times more than other grains and leading to a significant dietary 
exposure. The U.S. currently imports several varieties of basmati and jasmine 
rice, saki, a rice wine, and products made from rice from these endemic areas of 
the world without regulations on the arsenic level resulting in a potentially 
increased exposure to the population. 
4) Mechanisms of co-carcinogenesis 
 It is well established that arsenic can act to decrease DNA repair, increase 
HIF stabilization and alter DNA methylation by sequestering methyl donors [32]. 
A mechanism of carcinogenesis identified for environmental metals involves the 
disruption of pVHL-mediated regulation of oxygen sensing though the 
stabilization of HIFs [32]. However, it remains unclear and untested whether low 
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dose arsenic exposure could result in chronic stabilization of HIFs or lead to 
aberrant methylation of the VHL tumor suppressor gene to induce ccRCC.  
 One of the caveats of exploring this hypothesis is that mice are not 
sensitive to the loss of VHL and do not develop renal tumors upon VHL loss. 
However, it was found that chronic oral exposure of A/J mice to inorganic arsenic 
resulted in the development of lung tumors with loss of p16INK4a and RASSF1A 
tumor suppressor gene expression due to promoter hypermethylation [39]. In 
2001, the RAS association family 1 gene (RASSF1A), located at 3p21.3, was 
identified as a candidate lung tumor suppressor gene in humans as well [40]. 
Due to the genomic proximity of RASSF1A to chromosome 3p25, harboring the 
VHL gene, the methylation state of RASSF1A using bisulfite sequencing in 
human renal cell carcinomas was examined, and RASSF1A was found to be 
hypermethylated in both VHL-mutated and non-mutated ccRCC tumors [41]. It 
has been proposed that loss of both RASSF1A and VHL is required for the 
development of renal tumors in the mouse due to a functional redundancy in 
tumor suppression [42]. Until a mouse model of human ccRCC is developed, this 
only suggests that co-exposure to arsenic may result in epigenetic silencing of 
tumor suppressor genes, which may act to induce renal neoplasms. 
C. Susceptibility to renal toxicants 
1) Xenobiotic metabolism implicated in susceptibility 
 Genetic polymorphisms in drug metabolizing genes were found to 
increase renal cancer risk in TCE and arsenic exposed human populations [57, 
58]. TCE and inorganic arsenic are both conjugated to glutathione by glutathione-
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s-transferases during metabolism, and it is thought that these metabolites lead to 
the formation of nephrotoxic species [29]. Several epidemiological studies 
examining renal cancer risk associated with occupational exposure to TCE found 
a significant association among TCE-exposed subjects with at least one intact 
GSTT1 allele (active genotype; OR = 1.88) but not among subjects with two 
deleted alleles (null genotype; OR = 0.93) [59]. Similarly, with inorganic arsenic 
exposed individuals, a significantly increased risk (OR = 3.9) was observed in 
study subjects with specific genotypes of polymorphic genes GSTO1 and GSTO2 
[60]. Further, genes involved in other mechanisms, such as antioxidant defense, 
DNA repair, folate one-carbon metabolism and in arsenic transport across the 
cell membrane have all been shown to affect an individual’s susceptibility [61]. 
Together, we can infer from these studies that genetic variants play a role in 
increasing renal susceptibility to both TCE and arsenic exposure, and that this is 
likely due to differences in the formation of, or protection from, nephrotoxic 
metabolites. 
2) Arsenic susceptibility in mice 
 Mice are exceedingly efficient at metabolizing and extruding arsenic. For 
this reason, mice are relatively resistant to the effects of arsenic, unlike humans 
[43]. Inbred mouse strains have been used to examine the dependence of 
arsenic susceptibility on genetic background. Kimura et al. acutely exposed 
BALB/c and C57BL/6 mice to sodium arsenite and found that BALB/c mice 
showed elevated levels of BUN, creatinine, severe hemorrhage, tubular necrosis, 
and the disappearance of the PAS-positive brush border, while the C57BL/6 mice 
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had markedly attenuated injury, including a decreased intra-renal arsenic 
concentration. This difference in strain susceptibility was found to be due to an 
increased renal expression of heavy metal inducible proteins, like multidrug 
resistance-associated protein-1 (MRP-1), a renal transporter that acts to extrude 
arsenic from the kidney. Using a specific inhibitor of MRP-1, they were able to 
augment renal injury in the C57BL/6 strain [44]. Subsequent studies using the 
MDR p-glycoprotein ABC transporter knockout mouse showed that these mice 
accumulate arsenic in the kidney and are more susceptible to renal injury [45]. 
This suggests that inhibition of renal transport of arsenic can increase 
susceptibility to the development of renal injury in mice, and that the use of a 
transgenic transporter knockout mouse could be critical for the investigation of 
arsenic co-exposure in mice. 
3) Dietary factors can modulate susceptibility 
 Obesity, hypertension, and Type 2 diabetes are diseases that increase the 
risk for the development of renal cancer in humans, and are also associated with 
an improper diet and high body mass index [46]. Epidemiological studies have 
reported a significant association with the intake of saturated fat, red meat, 
cholesterol, and dietary starch with an increased risk for renal cell cancer, while 
intake of fats from vegetable sources, rich in ω-3 polyunsaturated fatty acids was 
associated with decreased risk [47, 48, 49]. Dietary modifications such as 
increased saturated fat are thought to contribute to the increase in carcinogenic 
potential of toxicants by altering baseline gene expression in histologically normal 
tissues and increasing serum lipids, hormones, and other metabolic factors [50].  
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 The “western diet” is a chow formulated for rodents which mimics the fat 
and calorie consumption of the western world, and has proven to be a useful tool 
in animal models of breast cancer, cardiovascular disease and colon cancer [51, 
52, 53]. Dietary modification studies using FVB/N, C57BL/6, and ICR mice on a 
control (10% fat) or high fat diet (60% fat) regimen found that relative to the 
control diet, mice on the high fat diet showed increased circulating insulin-like 
growth factor-I (IGF-1) and activation/phosphorylation of Akt and mTOR, two 
pathways frequently dysregulated in ccRCC. They also show that this effect was 
not dependant on genetic background [54]. These findings suggest that dietary 
fat consumption can modulate signaling through cell-surface receptors, like IGF-I, 
and in turn activate downstream pathways including Akt and mTOR. 
Interestingly, molecular evaluation of human kidney tumors has shown that 
expression levels of activated mTOR and Akt were significantly higher in tumor 
tissue when compared to normal tissue and further, enhanced Akt/mTOR and 
ERK/MAPK signaling was shown to be independent of VHL status, but instead 
dependent on HIF1 and HIF2 relative expression [55]. These studies indicate that 
diet is an environmental factor that plays an important role in the development of 
cancer in humans through the modulation of cell signaling, and that dietary 
formulation should be given serious consideration during the design of animal 
studies of carcinogenesis. 
4) Modeling genetic susceptibility using inbred mouse strains 
 Inbred mouse strains are the foundation of mammalian genetics research 
and continue to be a powerful tool in toxicological research [62]. Individuals of a 
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given strain are virtually homozygous and isogenic. In addition, with the 
sequencing of the mouse genome and many inbred strains, the naturally 
occurring genetic variation that drives their phenotypic differences can now be 
discovered at the gene level. Phenotypic variation between mouse lines, such as 
their toxicity and disease susceptibility traits, can be used to model certain 
human populations [63]. As such, the Laboratory Strain Diversity Panel (LSDP), 
a panel of inbred strains, has recently been used to identify susceptible and 
resistant strains to xenobiotic toxicity, as well as identification of biomarker genes 
whose expression strongly correlates with toxicity [64]. Many toxicity phenotypes 
are not controlled by only one gene, but are polygenetic, a product of many 
genes and their environment, and as such, are quantitative traits. 
 Quantitative trait loci (QTLs) are defined as segments of DNA containing 
the genes that underlie a quantitative trait. QTL mapping techniques are 
frequently used to identify genomic regions associated with variation in a 
phenotype of interest. The mapping of quantitative traits, such as susceptibility to 
renal injury, can be achieved through generation of a mouse mapping population, 
by controlled breeding of two inbred strains [65]. F2 or F3 intercross populations 
from diverse inbred strains are predicted to will exhibit variation in response to 
toxicant injury that can be then be mapped to the gene variants underling the 
response [65]. QTL mapping can be a powerful tool for the identification of 
genomic loci that confer susceptibility, potentially identifying human populations 
most at risk for developing renal injury due to exposure.  
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D. Specific aims 
 An unfortunate gap in toxicological research is the lack of experimental 
studies that explain how chronic, low dose exposures to a mixture of 
environmental pollutants, such as groundwater contaminants and dietary 
carcinogens, can modulate disease susceptibility and outcome. Co-exposures to 
elevated levels of TCE and inorganic arsenic through groundwater and dietary 
sources are frequently found in human populations and are thought to cause 
multiple organ toxicities in susceptible individuals. However due to conflicting 
species-specific differences in metabolism and detoxification, the interpretation of 
human relevance from rodent bioassays is subject to great debate. An example 
is the unclear etiology of kidney cancer in humans. It is known that VHL tumor 
suppressor gene mutations are found in the majority of human renal cell 
carcinomas, even in the earliest stages, and that VHL plays an important role in 
kidney cancer development. Epidemiological evidence suggests that VHL may 
be a target for environmental carcinogens such as TCE, which is thought to 
induce specific point mutations in the VHL gene. Furthermore, despite this known 
co-exposure, there is no data examining the role of arsenic as a possible co-
carcinogen in the kidney. We hypothesize that there is a mechanistic link 
between environmental co-exposures to TCE- and arsenic-induced renal 
toxicity that can be elucidated using genetically engineered model 
systems. Several deficiencies have been highlighted in TCE and arsenic 
research including 1) lack of experimental models with which to investigate the 
effects of the TCE-induced VHL mutations, 2) poor understanding of the linearity 
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of the dose response relationship, 3) lack of studies examining the effect of 
nutritional deficiencies, and 4) lack of consideration for susceptible populations in 
estimating risks [27]. There is, therefore, a pressing need for the development of 
in vitro and in vivo model systems with which to address these research 
deficiencies. Towards this end, the Specific Aims of this project were: 
 Specific aim 1: To develop an in vitro model to functionally 
characterize the TCE-associated P81S missense mutation on VHL tumor 
suppressor function to determine its relevance to renal tumorigenesis. It 
remains undetermined whether the TCE-associated point mutation in the VHL 
gene is sufficient to alter pVHLs function and tumor suppressor capacities. The 
hypothesis is that the P81S VHL mutation will disrupt the tumor suppressor 
function of VHL and lead to phenotypic characteristics similar to VHL disease-
causing mutations. To investigate a mouse embryonic stem cell system was 
used to model the P81S VHL missense mutation seen in human patients 
exposed to TCE. The P81S VHL mutant was compared to other clinically 
relevant VHL disease mutations for hypoxia-inducible transcription factor 
stabilization and activity, E3-complex interactions, and in vivo growth and 
differentiation characteristics. 
 Specific aim 2: To establish whether dietary factors influence kidney 
toxicity due to low dose inorganic arsenic exposure through gene 
expression analysis. Dietary deficiency in micronutrients as well as an 
imbalance in dietary fatty acids can play a large part by increasing susceptibility 
to environmental toxicants [34]. This becomes especially true in the case of 
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inorganic arsenic, where dietary co-factors play a role in the metabolism and 
detoxification [35]. As such, nutritionally deficient populations represent a unique 
and vulnerable subset of the population that is likely to be at increased risk for 
kidney toxicity due to arsenic exposure [36]. It is hypothesized that a nutrient 
poor western diet will increase arsenic toxicity in the kidney corresponding to 
altered gene expression pathways. To investigate this, FVB/N-Abcb1a/1b-/- 
mice, a multidrug resistant ABC transporter knockout model, will be exposed to 
environmentally-relevant concentrations of inorganic arsenic either on a standard 
rodent chow or a nutrient poor western diet for 10 weeks. Serum clinical 
chemistry, histopathology, and kidney gene expression by microarray analysis 
will be analyzed. 
 Specific aim 3: To develop an in vivo population-level model of TCE 
and arsenic co-exposure that can address genetic variation and dose-
response linearity. It is well known that drug metabolism and transport, as well 
as genetic variation and diet play roles in rodent-to-human differences in 
response to kidney injury. To address these three issues, we have a unique F3 
mouse intercross population derived from an intercross between the FVB/N-
Abcb1a/1b-/- strain, a multidrug resistant ABC transporter knockout mouse, and 
CAST/EiJ, a wild-derived strain from a different subspecies of Mus musculus. 
FVB/N-Abcb1a/1b-/- mice show decreased clearance of drug metabolites, 
including arsenic, and are more susceptible to injury in the kidney, while 
CAST/EiJ allows examination of genetic variability as this strain carries a 
completely different set of allele combinations, including VHL. It is hypothesized 
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that co-exposure to trichloroethylene and arsenic will act in an additive or 
synergistic fashion to induce renal toxicity, which can be modulated by 
genetically determined factors. To model human exposure, mice were 
administered TCE and arsenic via drinking water and chow, respectively, at 
environmentally-relevant concentrations for 52 weeks. After 16 weeks of 
exposure, serum and urine will be examined for markers of early renal injury and 
general organ toxicity, and observed whether the response to injury is attributed 
to genetic variation within the population.   
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Figure 1.1 
 
Regulation of Hypoxia Inducible Factors by pVHL in Normoxia and Hypoxia 
 
Illustration depicts the regulation of HIFα by pVHL through the formation of an E3-ubiquitin 
ligase complex. During normal oxygen, HIFα becomes hydroxylated at specific proline 
residues whereby allowing pVHL in association with Elongin B, Elongin C, Ring-box1 (Rbx1) 
and Cullin2 (Cul2) to recognize it as a substrate. HIFα is then polyubiquitinated and targeted 
for proteosomal degradation. Under hypoxic conditions, the lack of molecular oxygen 
prevents hydroxylation of HIF, allowing it to escape recognition by pVHL. HIFα then 
dimerizes with HIF-β and transcriptional co-activators CBP/p300 to transcriptionally activate 
hypoxia-responsive genes (i.e., Epo, VEGF, Glut1) involved in energy metabolism, 
angiogenesis and a host of other cellular processes.  
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Table 1.1 
 
Classification of VHL Disease Mutations 
 
VHL mutations identified in VHL disease patients reveal genotype-phenotype correlations 
with disease presentation. There are two subtypes, classified by no risk, low risk (type 1) or 
high risk (type 2) for pheochromocytoma, a neuroendocrine tumor of the adrenal glands. In 
each case a representative VHL missense mutations was identified to correlate with disease 
presentation [20]. VHL mutations also correlate with risk for development of renal cell 
carcinoma (RCC). Type 1 mutations are frameshift or truncating mutations which result in 
loss of VHL protein expression and have a high risk of RCC. Type 2A, 2B and 2C are point 
mutations with varying abilities to disrupt the VHL-HIF axis corresponding to RCC risk. In the 
case of the R200W mutation, there is not risk of tumor formation, only Chuvash 
Polycythemia.  
 
 
 
 
VHL Disease 
Subtype 
 
Representing 
Mutation 
 
Pheochromocytoma 
 
Renal Cell 
Carcinoma 
 
Type 1 
 
Loss of VHL 
 
Low 
 
High 
 
Type 2A 
 
Y112H 
 
High 
 
Low 
 
Type 2B 
 
R167Q 
 
High 
 
High 
 
Type 2C 
 
L188V 
 
High 
 
none 
Chuvash 
Polycythemia 
 
R200W 
 
none 
 
none 
 
 
 21 
 
 
 
 
Figure 1.2 
 
Metabolic Activation of Trichloroethylene 
 
Trichloroethylene (TCE) is primarily metabolized by the cytochrome p450 (CYP450) 
pathway to trichloroethanol, trichloroacetic acid and dichloroacetic acid. As a secondary 
pathway, TCE is conjugated by glutathione-S-transferase to form 1,2-DCVG which is 
hydrolyzed to S-1,2-dichlorovinylcysteine (DCVC). Then in the kidney, the renal specific 
cysteine-beta-lyase enzyme can then activate DCVC to a reactive thiol, resulting in 
nephrotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
ClCl
H Cl
Cl
H
SG
Cl
TCE
GSH Transferase
S
Cl
Cl
H
O
O
NH3
S-Glutathione Conjugate
1,2-DCVG
S-1,2-Dichlorovinylcysteine
Cl
Cl OH
Excretion
Mercapturic Acids
B-Lyase
Cl
OH
Chloral Hydrate
Cl
Cl OH
Cl
O
Cl
Cl OH
Cl Trichloroacetic Acid
ALDH
ADH
Trichloroethanol
Cl
Cl OH
O
Dichloroacetic AcidGlucuronide Conjugates
S C
Cl
HReactive Thiol
ClCl
H Cl
O
epoxide
CYP450
Nephrotoxicity
 22 
REFERENCES 
1: American Cancer Society. 2010 “Facts and Figures” http://www.cancer.org/ 
acs/groups/content/@epidemiologysurveilance/documents/document/acspc-
026238.pdf. Accessed March 5, 2011. 
 
2: Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B, Linehan WM. 
Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin 
North Am. 1993;20(2):207-16. 
 
3: Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney 
cancer. Clin Cancer Research 2004;10:6290S-5S. 
 
4:  Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer 
Surv. 1995;25:219-32. 
 
5: Steinberg P, Störkel S, Oesch F, Thoenes W. Carbohydrate metabolism in 
human renal clear cell carcinomas. Lab Invest. 1992;67(4):506-11. 
 
6: Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish 
two subtypes of sporadic VHLdeficient clear cell renal carcinoma. Cancer Cell. 
2008;14(6):435-46. 
 
7: Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing 
and cancer. Nat Rev Cancer. 2008;8(11):865-73. 
 
8: Tyers M, Rottapel R. VHL: a very hip ligase. Proc Natl Acad Sci U S A. 
1999;96(22):12230-2. 
 
9: Zatyka M, da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other 
novel targets for the von Hippel-Lindau tumor suppressor gene by expression 
array analysis and investigation of cyclin D1 genotype as a modifier in von 
Hippel-Lindau disease. Cancer Res. 2002;62(13):3803-11. 
 
10: Mikhaylova O, Ignacak ML, Barankiewicz TJ, et al. The von Hippel-Lindau 
tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large 
subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol. 
2008;28(8):2701-17. 
 
11: Hu CJ, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation 
domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha 
and HIF-2alpha. Mol Biol Cell. 2007;18(11):4528-42. 
 
12: Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the 
tumor phenotype. Curr Opin Genet Dev. 2007;17(1):71-7. 
 23 
13: Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, Ohh M. Dominant-negative 
HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle. 
2007;6(22):2810-6. 
 
14: Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. 
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of 
VHL loss in renal cell carcinoma. Cancer Cell.2002;1(3):247-55. 
 
15: Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is 
sufficient to suppress pVHLdefective tumor growth. PLoS Biol. 2003;1(3):E83 
 
16: Crossey PA, Richards FM, Foster K, et al. Identification of intragenic 
mutations in the von Hippel-Lindau disease tumour suppressor gene and 
correlation with disease phenotype. Hum Mol Genet. 1994;3(8):1303-8. 
 
17: Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-
1alpha regulation by disease-causing pVHL mutations correlate with patterns of 
tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 
2001;10(10):1029-38. 
 
18: Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of 
pVHL is sufficient to cause HIF dysregulation in primary cells but does not 
promote tumor growth. Cancer Cell. 2003;3(1):75-88. 
 
19: Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, 
Rathmell WK. VHL Type 2B gene mutation moderates HIF dosage in vitro and in 
vivo. Oncogene. 2009;28(14):1694-705. 
 
20: Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon 
MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific 
mutations. Cancer Res. 2004;64(23):8595-603. 
 
21: Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC 
complex form and function. PLoS ONE. 2008;3(11):e3801. 
 
22: Shiao YH, Rice JM, Anderson LM, Diwan BA, Hard GC. von Hippel-Lindau 
gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors. J 
Natl Cancer Inst. 1998;90(22):1720-3. 
 
23: Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell 
renal cell carcinoma: association with advanced tumor stage and a novel hot spot 
mutation. Cancer Res. 2000;60(7):1942-8. 
 
24: Kumar P, Prasad AK, Dutta KK. Steroidogenic alterations in testes and sera 
of rats exposed to trichloroethylene (TCE) by inhalation. Hum Exp Toxicol. 
2000;19(2):117-21. 
 24 
25: Chiu WA, Caldwell JC, Keshava N, Scott CS. Key scientific issues in the 
health risk assessment of trichloroethylene. Environ Health Perspect. 
2006;114(9):1445-9. 
 
26: Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T. 
Trichloroethylene exposure and specific somatic mutations in patients with renal 
cell carcinoma. J Natl Cancer Inst.1999; 91(10):854-61. 
 
27: National Research Council (U.S.), National Research Council (U.S.). 
Committee on Human Health Risks of Trichloroethylene. Assessing the human 
health risks of trichloroethylene: key scientific issues ;National Academies Press, 
2006. 
 
28: National Toxicology Program. NTP Carcinogenesis Studies of 
Trichloroethylene (Without Epichlorohydrin)(CAS No. 79-01-6) in F344/N Rats 
and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1990; 
243:1-174. 
 
29: Mally A, Walker CL, Everitt JI, Dekant W, Vamvakas S. Analysis of renal cell 
transformation following exposure to trichloroethene in vivo and its metabolite S-
(dichlorovinyl)-L-cysteine in vitro. Toxicology. 2006;224(1-2):108-18. 
 
30: Kleymenova E, Everitt JI, Pluta L, Portis M, Gnarra JR, Walker CL. 
Susceptibility to vascular neoplasms but no increased susceptibility to renal 
carcinogenesis in Vhl knockout mice. Carcinogenesis. 2004;25(3):309-15. 
 
31: Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice 
with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer 
Res. 2006;66(5):2576-83. 
 
32: Salnikow K, Zhitkovich A. Genetic and epigenetic mechanisms in metal 
carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res 
Toxicol. 2008;21(1):28-44. 
 
33: Guha Mazumder DN. Chronic arsenic toxicity & human health. Indian J Med 
Res. 2008;128(4):436-47. 
 
34: Tseng CH. A review on environmental factors regulating arsenic methylation 
in humans. Toxicol Appl Pharmacol. 2009;235(3):338-50. 
 
35: Frumkin H, Thun MJ. EPA re-establishes lower limit for drinking water; New 
standard fully in effect by 2006. CA Cancer J Clin 2001;51: 254-262 
 
36: Tchounwou PB, Wilson B, Ishaque A. Important considerations in the 
development of public health advisories for arsenic and arsenic-containing 
compounds in drinking water. Rev Environ Health.1999;14(4):211-29. 
 25 
37: Kumar A, Adak P, Gurian PL, Lockwood JR. Arsenic exposure in US public 
and domestic drinking water supplies: A comparative risk assessment. J Expo 
Sci Environ Epidemiol. 2009. 
 
38: Stone R. Food safety. Arsenic and paddy rice: a neglected cancer 
risk?.Science. 2008;321(5886):184-5. 
 
39: Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to 
inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A 
and induces lung cancer in A/J mice. Toxicol Sci. 2006;91(2):372-81. 
 
40: Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor 
suppressor gene RASSF1A is intensely methylated in primary small cell lung 
carcinomas. Oncogene. 2001;20(27):3563-7. 
 
41: Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, 
RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. 
Proc Natl Acad Sci U S A. 2001; 98(13):7504-9. 
 
42: Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens 
S, Jonas U, Serth J. RASSF1A promoter methylation and expression analysis in 
normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 
2007;6:49. 
 
43: Clewell HJ, Thomas RS, Gentry PR, et al. Research toward the development 
of a biologically based dose response assessment for inorganic arsenic 
carcinogenicity: a progress report. Toxicol Appl Pharmacol. 2007;222(3):388-98. 
 
44: Kimura A, Ishida Y, Wada T, Yokoyama H, Mukaida N, Kondo T. MRP-1 
expression levels determine strain-specific susceptibility to sodium arsenic-
induced renal injury between C57BL/6 and BALB/c mice. Toxicol Appl 
Pharmacol. 2005;203(1):53-61. 
 
45: Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD. Multidrug-resistance 
mdr1a/1b double knockout mice are more sensitive than wild type mice to acute 
arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology. 2002; 
170(1-2):55-62. 
 
46: Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation 
of renal cell carcinoma. Urol Clin North Am. 2008;35(4):581-92. 
 
47: Bidoli E, Talamini R, Zucchetto A, et al. Macronutrients, fatty acids, 
cholesterol and renal cell cancer risk. Int J Cancer. 2008;122(11):2586-9. 
 
 26 
48: Lee JE, Spiegelman D, Hunter DJ, Albanes D et al., Fat, protein, and meat 
consumption and renal cell cancer risk: a pooled analysis of 13 prospective 
studies. J Natl Cancer Inst. 2008;100(23):1695-706. 
 
49: Brock KE, Gridley G, Chiu BC, Ershow AG, Lynch CF, Cantor KP. Dietary fat 
and risk of renal cell carcinoma in the USA: a case-control study. Br J Nutr. 
2009;101(8):1228-38. 
 
50: Yang K, Yang W, Mariadason J, Velcich A, Lipkin M, Augenlicht L. Dietary 
components modify gene expression: implications for carcinogenesis. J Nutr. 
2005;135(11):2710-4. 
 
51: Akiyama TE, Lambert G, Nicol CJ, et al. Peroxisome proliferator-activated 
receptor beta/delta regulates very low density lipoprotein production and 
catabolism in mice on a Western diet. J Biol Chem. 2004;279(20):20874-81. 
 
52: Gordon RR, Hunter KW, La Merrill M, Sørensen P, Threadgill DW, Pomp D. 
Genotype X diet interactions in mice predisposed to mammary cancer: II. Tumors 
and metastasis. Mamm Genome. 2008;19(3):179-89. 
 
53: Chen H, Hansen MJ, Jones JE, Vlahos R, Anderson GP, Morris MJ. 
Detrimental metabolic effects of combining long-term cigarette smoke exposure 
and high-fat diet in mice. Am J Physiol Endocrinol Metab. 2007;293(6):E1564-71. 
 
54: Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, DiGiovanni J. 
Dietary energy balance modulates signaling through the Akt/mammalian target of 
rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 2008;1(1):65. 
 
55: Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish 
two subtypes of sporadic VHL deficient clear cell renal carcinoma. Cancer Cell. 
2008;14(6):435-46. 
 
56: Hernández-Zavala A, Matoušek T, Drobná Z, et al. Speciation analysis of 
arsenic in biological matrices by automated hydride generation-cryotrapping-
atomic absorption spectrometry with multiple microflame quartz tube atomizer. J 
Anal At Spectrom. 2008;23:342. 
 
57. Brüning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of 
polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with 
long-term high occupational exposure to trichloroethene. Arch Toxicol.1997; 
71(9):596-9. 
 
58: Colin P, Koenig P, Ballereau C, et al. Sporadic upper urinary tract urothelial 
cell carcinomas: identification of interaction between toxic carcinogens and 
individuals genetic susceptibility. Prog Urol. 2010;20(1):1-10. 
 
 27 
59: Moore LE, Boffetta P, Karami S, Brennan P et al., Occupational 
trichloroethylene exposure and renal carcinoma risk: evidence of genetic 
susceptibility by reductive metabolism gene variants. Cancer Res. 2010; 
70(16):6527-36. 
 
60: Wang YH, Yeh SD, Shen KH, et al. A significantly joint effect between 
arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, 
GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol. 
2009;241(1):111-8. 
 
61: Hernández A, Marcos R. Genetic variations associated with inter-individual 
sensitivity in the response to arsenic exposure. Pharmacogenomics. 2008; 
9(8):1113-32. 
 
62: Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, 
Fisher EM. Genealogies of mouse inbred strains. Nat Genet. 2000;24(1):23. 
 
63: Threadgill DW, Hunter KW, Williams RW. Genetic dissection of complex and 
quantitative traits: from fantasy to reality via a community effort. Mamm Genome. 
2002;13(4):175-8. Review. PubMed PMID: 11956758. 
 
64: Harrill AH, Ross PK, Gatti DM, Threadgill DW, Rusyn I. Population-based 
discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory 
strain diversity panel. Toxicol Sci. 2009;110(1):235-43. 
 
65: Xiao J, Liang Y, Li K, et al. A novel strategy for genetic dissection of complex 
traits: the population of specific chromosome substitution strains from laboratory 
and wild mice. Mamm Genome. 2010;21(7-8):370-6. 
 
66: Zou F, Gelfond JA, Airey DC, Lu L, Manly KF, Williams RW, Threadgill DW. 
Quantitative trait locus analysis using recombinant inbred intercrosses: 
theoretical and empirical considerations. Genetics. 2005 ;170(3):1299-311. 
 
 
Chapter Two: 
THE TCE-ASSOCIATED VHL MUTATION DISRUPTS 
HIF REGULATION AND PROMOTES TUMOR GROWTH 
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A. Abstract 
 Trichloroethylene (TCE) is a suspect kidney carcinogen that has been 
associated with a specific missense mutation (P81S) in the von-Hippel Lindau 
(VHL) tumor suppressor gene. Although VHL is commonly mutated in sporadic 
renal cell carcinoma, little is known about the functional consequences of the 
P81S VHL mutation in the context of tumor suppressor function and disease 
relevance. pVHL plays a critical role in regulating cellular response to hypoxia, 
and while some mutations in VHL disrupt its function as an E3 ubiquitin ligase 
targeting hypoxia-inducible factors (HIF) for degradation during normoxia, others 
have been shown not to affect the HIF axis. Consequently, we hypothesize that 
the P81S VHL mutation may alter pVHL function through disruption of complex 
formation, leading to loss of tumor suppressor activity. In this study, we have 
modeled the TCE-associated VHL gene mutation using an embryonic stem cell 
system where the endogenous wild-type mouse Vhl gene was replaced with the 
human P81S VHL mutant gene. This allows an evaluation of the consequences 
of this mutation on pVHL function, HIF degradation and in vivo teratoma 
formation. We found that the P81S mutant has partial loss of E3-complex 
formation allowing HIF stabilization during normal oxygen conditions. When 
grown in vivo, the P81S teratomas also display phenotypic evidence of increased 
HIF signaling, as well as a novel anti-apoptotic phenotype. Transcript analysis 
further suggested a mitochondrial-mediated mechanism of apoptosis avoidance. 
We purport that the P81S mutation represents a unique disease-relevant 
mutation, which contributes to both initiation as well as promoting tumor growth.   
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B. Introduction 
 TCE is an organic solvent that was once used heavily in industry and is a 
suspect kidney carcinogen in both animals and humans. Human studies have 
linked exposure to TCE with a specific missense mutation C454T in the von 
Hippel-Lindau tumor suppressor gene (VHL) [1, 2, 3]. This mutation results in a 
single amino acid change from proline to serine at codon 81 of the VHL protein 
(pVHL), but it remains undetermined whether this mutation has a functional 
consequence on tumor suppressor activity. While the findings linking TCE 
exposure to kidney cancer are of great relevance to public health, our lack of 
understanding of the tumorigenic potential of the P81S mutation in the kidney 
has hampered risk assessment of TCE.  
 VHL is mutated in over 80% of sporadic clear cell renal cell carcinomas 
(ccRCC), and for this reason, it is thought to be an early and key event in the 
development of kidney cancer in humans [4]. Some missense mutations in VHL 
disrupt its function as part of an E3 ubiquitin ligase complex targeting hypoxia-
inducible factor transcription factors (HIF) for degradation during normoxia [5, 6]. 
The transcriptional upregulation of HIF target genes is thought to mediate the 
majority of the aberrant phenotypes associated with ccRCC [7]. pVHL also plays 
a role in cell cycle arrest by stabilizing the cyclin-dependent kinase inhibitor p27 
[8]. Loss of normal pVHL function is thought to initiate and drive the tumorigenic 
process however it has been observed that not all mutations have the same 
tumorigenic potential [9].  
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 The lack of an experimental animal model with which to investigate the 
effects of the TCE-associated mutation in VHL and kidney tumor development 
has hindered mechanistic studies. Unlike what is seen in humans, VHL loss does 
not appear to be sufficient for tumorigenesis in mice [10, 11] and heterozygosity 
does not predispose to carcinogen-induced neoplasia [12]. As such, it remains 
debatable whether alterations in VHL alone are sufficient to trigger tumorigenic 
processes in the kidney. In vitro embryonic stem cell systems have been 
promising in characterizing the genotype-phenotype correlations of specific 
mutations found in VHL disease families, and thus have given us insight into the 
tumor suppressor functions of pVHL [9].  
 VHL was first identified as an important tumor suppressor for its role in 
VHL disease, a hereditary cancer syndrome resulting in a variety of tumors in 
affected patients [13]. Among VHL disease family members, strong genotype-
phenotype correlations have been observed between type and location of the 
mutation and the resulting tumor spectrum [9, 14]. As such, not all mutations in 
the gene predispose to renal cell cancer in affected families. As an example, the 
R167Q VHL missense mutation is frequently found in VHL disease families that 
develop ccRCC, and has been found to result in partial loss of HIF regulation and 
a decrease in tumor suppressor activity [15, 16]. In a separate example, the 
germline mutation R200W is not correlated with the occurrence of renal cell 
carcinomas in familial VHL disease, but only predisposes patients to Chuvash 
polycythemia, further confirming that not all mutated VHL bases contribute to 
tumorigenesis in the kidney [17].   
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 In the investigation presented here, we have utilized an in vitro system to 
characterize the VHL P81S mutation to examine both the functional 
consequence on tumor suppressor activity as well as to understand its possible 
role in the progression of renal tumorigenesis. 
C. Methods 
Cell lines and growth conditions. 
  Vhl-/- embryonic stem (ES) cells were generated as previously described 
[14]. In this study, Vhl-/- ES cells expressing wild-type human VHL protein 
(pVHL) as well as the R167Q clones were used for comparison. ES cells were 
grown in high glucose DMEM without sodium pyruvate, supplemented with 2mM 
L-glutamine, 1x non-essential amino acids (all from Gibco Invitrogen), 0.1mM 
betamercaptoethanol (Sigma), and 150uL LIF. All cells were grown in a 37°C 
incubator under 5% CO2 and were passaged at 3-day intervals. Cells were used 
in experiments during a 4-month period at approximately 70% confluence. 
Construct generation.  
 cDNA from the human VHL gene was ligated into the multiple cloning site 
of pBluescript II KS+ vector using Hind III. For mammalian expression constructs, 
the hemagglutinin epitope tag (GKPIPNPLLGLDST) and PolyA tail was added to 
the coding region by sequential PCR along with Bam HI and Hind III sites 
allowing the resultant PCR product to cloned into pStationII vector under control 
of the EF1 promoter and 4F2 enhancer, also containing the hygromycin 
resistance gene for clonal selection.  
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Site-directed mutagenesis.  
 Site-directed mutagenesis of the pST-HA-VHL parental construct to 
mutate the proline at nucleotide position 454 to a serine residue was performed 
using the Quikchange II XL site-directed mutagenesis kit as per the 
manufacturer’s protocol (Stratagene). The mutagenesis primer sets used are 
listed with the specific base changes underlined: Forward 5’-
GCAATCGCAGTTCGCGCGTCG; Reverse 5’-CGACGCGCGAACTGCGATTGC. 
The following sequencing primer was used for verification of the nt454 VHL 
mutation: 5’-TCGAAGAGTACGCCCCTGAAGAA-3’. 
Electroporation into Vhl-/- stem cells.  
 Vhl-/- cells were seeded at 1x107cells/well onto gelatin coated 100mm 
dishes and propagated overnight. Cells were trypsinized and washed twice using 
electroporation medium (serum-free, unsupplemented DMEM). The cells were 
resuspended in 0.8mL electroporation medium at 2 X l07cells/mL. Cell 
suspensions were mixed with 10ug of DNA at 25°C for 10min before 
electroporation. The cells were pulsed at 250 V with 0.68-0.72 time constant 
using a Bio-Rad GenePulser (Bio-Rad, Hercules,CA). The treated cells were kept 
at 25°C for another 10 min before re-plating. At 24h, the plates were rinsed with 
PBS once before adding the new culture medium containing 200uM hygromycin 
selection media. Selection media was replaced daily for 14 days before the 
selection of clones. Clones were tested for HA-VHL expression via western blot. 
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Hypoxia treatments.  
 ES cells expressing the P81S mutation, as well as previously generated 
pVHL cell lines: R167Q, WT and null were plated on gelatin-coated 60mm cell 
culture dishes and allowed to adhere overnight. Cells were subsequently 
exposed to 100uM CoCl2, a hypoxia mimic, while normoxic controls received 
media replacement. Exposure duration was 16hrs at 37ºC and 5% CO2 in a 
humidified incubator. After treatment, cell monolayers were washed twice with 
PBS and were either scraped into 175µL cold PBS and snap frozen for RNA 
isolation or lysed in the dish by the addition of 175µL lysis buffer ( 900mM NaCl, 
0.5% Nonidet P-40, 10 µg/ml leupeptin, and 20 µg/ml aprotinin for western blot 
analysis. Cell suspensions were immediately incubated on ice for 5min and 
centrifuged at 10,000rpm at 4°C for 10 min and protein concentrations were 
determined by the BCA protein assay (Pierce, Rockford, IL) with bovine serum 
albumin as the standard. Samples were prepared using 35µg total protein mixed 
with 5x sample buffer containing 1M DTT and heated in boiling water bath for 
10min. Samples were then run on a 8% SDS-PAGE gel. 
Immunoprecipitation of E3-complex.  
 Based on the predicted interaction domains for wild-type pVHL, we tested 
the effect the P81S mutation on the protein-protein interactions with the E3-
complex, and compared those interactions with the other clinically relevant VHL 
mutations, Y112H and R167Q. IP experiments were performed as described 
using the Pierce Mammalian HA-tag Co-IP kit (Pierce, Rockford, IL). Cells were 
gently lysed using supplied IP buffer supplemented with protease inhibitors 
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(20μg/ml). 700ug protein extract was incubated with 1ug HA-tag IgG conjugated 
to 6ul Protein A/G agarose beads (Pierce) for 24 hours at 4°C. Columns were 
washed with 500 ul TTBS three times for 10 minutes at 4°C and protein eluted by 
boiling in 30 ul 1X non-denaturing sample buffer. Samples were centrifuged 
through supplied column to remove IgG beads and reboiled with 1mM DTT for 
10min. Supernatants were resolved by SDS-PAGE and western blotting as 
described below. 
Western blot analysis. 
 To evaluate the ability of the P81S mutant to alter HIF degradation as well 
as E3-complex interactions under normoxic and hypoxic conditions, we 
quantified protein levels by western blot. Protein samples were resolved by 
denaturing electrophoresis using polyacrylamide gels (SDS-PAGE) and were 
electrophoretically transferred to nitrocellulose membrane. Immunochemical 
staining was carried out with varying concentrations of primary antibody diluted in 
1%milk/TBST buffer incubated at times ranging from 2 hours to overnight at 4°C. 
Specific primary antibodies against pVHL (Cell Signaling), HIF1α (Cayman), HIF2 
(Genetex), HA-tag (Abcam), Cul2 (Abcam), and Elongin C (Santa Cruz) were 
purchased from commercially available vendors. HRP-conjugated secondary 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Blots were washed with three changes of TBST for a total of 30 min. The blot 
was then incubated in 1%milk/TBST buffer containing a 1:10,000 dilution of goat 
anti-rabbit, donkey anti-goat or goat anti-mouse-HRP secondary antibodies for 2 
h at 24°C and washed in TTBS or PBST. Before detection, the blots were rinsed 
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PBS for 1 min. Bands were visualized with the enhanced chemiluminescence 
(ECL) kit as specified by the manufacturer (Amersham Biosciences, Piscataway, 
NJ). Multiple exposures of each membrane were produced using X-ray film.  
RNA isolation.  
 To quantify changes in gene expression, total RNA from teratomas and 
cell pellets was isolated using RNeasy® Mini Kits (Qiagen, Valencia, CA) per 
manufacturer's protocol. Total RNA was quantified with a NanoDrop®ND-1000 
Spectrophotometer (NanoDrop Technologies, Rockland, DE). RNA quality was 
determined with an Agilent BioAnalyzer (Agilent Tech. Inc., Santa Clara, CA). 
Quantitative RT-PCR. 
 cDNA was prepared from total RNA using Applied Biosystems cDNA 
Archive kit, with an initial concentration of RNA between 10-40ng/uL. For 
quantitative RT-PCR, validated primer/probe sets were purchased from Applied 
Biosystems. Samples were prepared with 20ng cDNA per reaction according to 
manuacturer’s instructions (ABI, Carlsbad CA). Samples were run in a 96-well 
plate using the Stratagene Mx2000 qRT-PCR machine. Data was normalized to 
loading control beta-glucuronidase or beta-actin and results were calculated 
using ΔΔCt method.  
In vivo teratoma formation assay. 
 To evaluate the effect of the P81S VHL mutation on tumor growth, 
vascularization, hypoxic regions, HIF transcriptional activity and cellular 
differentiation, we performed an in vivo teratoma assay. Briefly, the teratoma 
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assay was performed using two clones of the P81S ES cell line, P81S.4 and 
P81S.12, as well as wild-type cells and R167Q mutant lines. Cells were grown to 
70% confluency under normal conditions. Female nude mice (n = 4) between 6-8 
weeks of age were injected subcutaneously in bilateral flanks with 1x106 cells of 
each HA-VHL cell line suspended in saline. Tumor growth was measured three 
times a week using calipers until tumors reached a maximum dimension of 1cm. 
To examine tumor hypoxia, mice were injected with 60mg/kg Hypoxyprobe™ 
(HPI, Inc., Burlington MA) one hour before sacrifice by CO2. Tumors were 
excised within 5 minutes and samples were either flash frozen for gene 
expression and protein analysis or formalin fixed and paraffin embedded for 
histology and immunohistochemistry.  
Immunohistochemistry.  
 To evaluate teratomas for proliferation, apoptosis, and DNA damage, IHC 
was performed. Formalin-fixed, paraffin-embedded sections (6μm) were mounted 
on glass slides. Sections were deparaffinized in xylene, rehydrated in a series of 
graded alcohol concentrations, and placed in PBS with 1% Tween 20. 
Immunostaining was performed using standard laboratory procedures with 
primary antibody dilutions 1:1000 H2AX; 1:500 Ki67 (Abcam). Secondary 
detection was done with biotinylated rabbit, or goat specific antibodies, ABC 
enhancement kit (Vector, Burlingame CA), and DAB detection reagent (Vector).  
Apoptosis Staining was performed using the ApopTag® In Situ Apoptosis 
Detection Kit (Millipore) according to manufacturer’s protocol. Slides were 
counterstained with hematoxylin to facilitate cell counts. In order to ensure the 
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quantitative measurement of each immunoreaction, all teratomas were compared 
were processed in parallel. Quantitative analysis of immunostained sections was 
performed using BIOQUANT software (BIOQUANT Image Analysis, Nashville 
TN) by averaging percent positively stained cells to total cells within 6 random 
fields at 200×.  
Hypoxia measurements. 
 Hypoxyprobe or pimonidazole hydrochloride forms adducts with protein 
thiol groups under low oxygen conditions (<10mm Hg). To examine tumor 
hypoxia, mice were injected with 60mg/kg Hypoxyprobe™ one hour before 
sacrifice by CO2. Tumors were excised within 5 minutes and were sliced, formalin 
fixed and paraffin embedded for immunohistochemical detection of protein 
adducts. Anti-Hypoxyprobe-1 is a monoclonal antibody that detects protein 
adducts of Hypoxyprobe™ in hypoxic cells. Staining was performed according to 
manufacturer’s protocol (HPI, Inc. Burlington MA). Three serial sections per 
teratoma were quantified by choosing evaluating 5 fields per 6uM slice. 
Microarray analysis. 
 Microarray experiments were performed using GeneChip® Mouse ST 
Gene 1.0 whole genome arrays from Affymetrix (Santa Clara, CA) at the UNC 
Genomics Core Facility. Total RNA samples were processed following a 
standard one-cycle eukaryotic target preparation protocol from Affymetrix. Briefly, 
total RNA was first reverse-transcribed using T7-oligo(dT) promoter primer in the 
first-strand cDNA synthesis reaction. Following second-strand cDNA synthesis, 
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the double stranded cDNA was purified and served as a template in the 
subsequent in vitro transcription (IVT) reaction. The IVT reaction was carried out 
in the presence of T7 RNA Polymerase and a biotinylated nucleotide 
analog/ribonucleotide mix for complementary RNA (cRNA) amplification and 
biotin labeling. Biotinylated cRNA targets were then purified, fragmented, and 
hybridized to GeneChip® array during the overnight incubation at 45°C in a 
rotating hybridization oven. After hybridization, the arrays were stained with 
streptavidin-phycoerythrin in the GeneChip® Fluidics station and then scanned 
using Affymetrix GeneChip® Scanner (laser filter set at 570 nm; pixel size 2.5 
μm). The array image data were acquired, and the fluorescent signal intensities 
were quantified using Affymetrix® GCOS software with following settings of 
quantitation parameters: Alpha1 = 0.05, Alpha2 = 0.065, Tau = 0.015, Gamma1H 
= 0.0045, Gamma1L = 0.0045, Gamma2H = 0.006, Gamma2L = 0.006, 
Perturbation = 1.1, Target Intensity = 150. 
Pathway analysis and statistics. 
 The Affymetrix Mouse ST Gene 1.0 array has approximately 27 probes 
spread across each of the 28,853 genes represented on the array, providing a 
more complete and more accurate picture of gene expression than 3'-based 
expression array designs. The array probe set sequences were derived from 
GenBank®, Ensembl, dbEST, and RefSeq. Gene expression data (CEL files) 
were analyzed using Partek® Genomic Suite, version 6.3 (Partek Inc., St. Louis 
MO). Gene expression data were normalized by robust multi-array analysis 
(RMA) and analysis of variance was performed using Partek® software. We 
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identified differentially expressed genes between classes using the non-
parametric rank-product method (p-value <0.05 and 0.01) and log2 expression 
values for each gene were generated. Canonical pathway analysis was 
generated through the use of Ingenuity Pathways Analysis (IPA) (Ingenuity® 
Systems, www.ingenuity.com). Canonical pathway analysis was measured in two 
ways: (1) a ratio of the number of genes from the data set that map to the 
pathway divided by the total number of genes that map to the canonical pathway, 
and (2) Fischer's exact test to calculate a p-value.  
D. Results 
P81S pVHL expression in Vhl−/− embryonic stem cells. 
 Site-directed mutagenesis was performed on plasmid constructs 
containing HA-tagged human VHL cDNA to generate the C454T missense 
mutation at codon 81 of pVHL, representing the TCE-exposure associated P81S 
mutation. Forty colonies were isolated and the VHL cDNA sequenced to verify 
the C454T mutation and to ensure no other mutations in the gene were 
introduced (Figure 2.1). Then, Vhl−/− embryonic stem cells generated as 
described previously [14] were transfected with plasmid encoding the HA-tagged 
human VHL P81S cDNA. Twenty-eight transgenic clones were selected for pVHL 
P81S expression by western blot, and two representative clones were selected 
that matched the expression levels of the VHL WT and VHL R167Q cell lines 
previously described [9] to avoid effects of overexpression. 
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VHL P81S mutation alters E3-complex and disrupts HIF regulation in vitro. 
 pVHL plays an important role in the regulation of HIF during normal 
oxygen conditions via its activity as a substrate recognition protein in the E3-
complex [9]. As a first step, we examined the ability of the P81S mutant to 
interact with the E3-complex and promote ubiquitination of HIF under normoxia. 
Unlike VHL WT cells which retain their interaction with Elongin C and Cullin 2, 
extracts from the VHL P81S mutant and VHL R167Q disease mutant did not pull 
down Elongin C but retained interaction with Cullin 2 (Figure 2.2A). Our findings 
are consistent with previous findings that the VHL R167Q disease mutant 
undergoes partial abrogation of the E3-complex through loss of interaction with 
Elongin C, and is only partially able to regulate HIF [16].   
 We then examined the ability of the pVHL mutants to degrade HIF protein 
during normoxic and hypoxic conditions. Two representative clones of the VHL 
P81S mutant as well as the Vhl-/-, VHL WT, VHL R167Q cell lines were analyzed 
for HIF1a protein expression after 16hrs of growth in the presence of normal 
oxygen (21% O2) or hypoxia mimetic (CoCl2) (Figure 2.2B). As a positive control, 
the lack of pVHL expression in Vhl-/- cells allowed HIF1 to be stabilized under 
normoxic conditions with no further increase during hypoxia. When Vhl-/- cells 
were complimented with the wild-type human pVHL, HIF1 ubiquitination and 
degradation was restored during normoxia. In contrast, when we examined the 
TCE-associated VHL P81S mutant and the VHL R167Q disease mutant, we 
found that HIF1 was partially stabilized during normoxia, consistent with the idea 
that loss of Elongin C binding perturbed E3-complex function. 
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VHL P81S mutant continues to suppress HIF1α targets in vitro.   
 Given the observation that HIF1 protein was stabilized in both the TCE-
associated P81S mutant and the R167Q disease mutant, we next determined 
whether the increase corresponded to an increase in HIF1 transcriptional activity. 
We performed quantitiative RT-PCR on the ES cell lines to examine HIF 
transcriptional target gene expression. Despite the partial stabilization of HIF1 
during normoxia (Figure 2.2B) we were unable to observe HIF transcriptional 
activity during normoxic conditions (not shown). This may be due to the limited 
targets examined, as only four target genes were quantified. On the other hand, 
the R167Q cells showed an increase in HIF target expression consistent with HIF 
protein stability, suggesting that the P81S pVHL mutant may be binding other 
HIF targets.  
VHL P81S mutant displays a marked growth advantage and differentiation 
in the teratoma assay. 
 One disadvantage of the embryonic stem cell system is the inability to 
examine the contribution of HIF2 transcriptional activity to the overall phenotype 
of pVHL mutants [9]. To examine the 3D growth and differentiation of the VHL 
stem cell lines, we performed an in vivo teratoma assay in nude mice, measuring 
tumor growth over 4 weeks followed by histopathological examination (Figure 
2.3A). Strikingly, we found that the VHL P81S mutant displayed a 3-fold increase 
in tumor volume over VHL WT cells and a 6-fold increase over VHL R167Q cells 
(Figure 2.3B). We also observed an increase in differentiation of the P81S 
teratomas over the WT and R167Q (Figure 2.3C). However, no significant 
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increase in HIF2 protein stabilization was observed for P81S when compared to 
WT, as both of these teratomas are likely hypoxic (Figure 2.4A). We did see 
increases in HIF target gene expression likely contributed by both HIF1 and HIF2 
protein stability (Figure 2.4B). HIF1 plays a role in cellular differentiation through 
Notch signaling [18], so while the P81S and R167Q mutants show similar 
dysregulation of HIF, their response to the tumor microenvironment may be re-
directing their HIF target expression. The relative growth rates of WT and R167Q 
teratomas as well as the histological features were consistent with previous 
studies [9]. Therefore, the remarkable growth advantage displayed by the P81S 
mutant suggests that the mutation may be affecting alternate functions of pVHL 
or altering HIF activity. 
VHL P81S teratoma growth is not due to increased proliferation but 
decreased apoptosis. 
 To explore the growth phenotype of the P81S, we analyzed the WT, 
R167Q and P81S ES cell teratomas for proliferative activity using the marker 
Ki67. The relative proliferation index between WT and P81S teratomas was not 
significantly different (Figure 2.5A), suggesting that a proliferative phenotype was 
not the reason for the increased tumor volume. We then investigated whether an 
apoptotic defect could be the source of the increased growth using an apoptosis 
specific stain based on modification the 3’-OH end fragments utilizing terminal 
deoxynucleotidyl transferase (TdT) and fluorescent detection. The results of the 
apoptosis stain showed there was a significant reduction in the percent of 
apoptotic cells compared to WT or R167Q teratomas (Figure 2.5B). This anti-
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apoptotic phenotype is a novel finding for a VHL disease mutant and suggests 
the TCE-exposure associated mutant may be capable of evading apoptotic 
signals, allowing teratocarcinoma growth. 
Mitochondrial biogenesis as mechanism of apoptotic aversion and cell 
survival in the VHL P81S mutant. 
 Investigations into pVHL tumor suppressor activity suggest that there are 
both HIF-dependent and HIF-independent mechanisms of apoptotic regulation 
[19]. To evaluate the role of the P81S mutation in the anti-apoptotic phenotype, 
we performed a whole genome microarray analysis on the ES cell teratomas. We 
performed unsupervised hierarchical clustering of four replicate P81S teratomas 
and three replicate WT and R167Q teratomas followed by analysis of variance of 
all genes (Figure 2.6). The dendrogram shows that samples segregated based 
on genotype, with the WT and R167Q mutant teratomas appearing more similar 
to each other compared to the P81S mutant, ~2622 genes were differentially 
expressed (p≤0.001) across all three genotypes. Performing a t-test analysis to 
characterize genes differentially expressed by genotype (p≤0.001) further 
confirmed the striking differences in gene expression between the P81S and the 
WT teratomas: ~2293 genes were found to be differentially regulated (Figure 
2.7A). Canonical pathway analysis revealed that the up-regulation of DNA 
damage/G2 checkpoint, G1/S Checkpoint, and p53 signaling in the WT 
teratomas, suggestive of increased apoptosis and DNA damage. On the other 
hand, in the P81S teratomas an up-regulation of HIF signaling and the Vitamin 
D3 pathway suggests cellular growth and HIF target gene expression. These 
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pathway networks are consistent with our histological findings, as the WT 
teratomas displayed an increase in H2AX foci formation (not shown) and an 
increase in apoptosis (Figure 2.5B) compared to P81S teratomas, which showed 
an increase in HIF target gene expression (Figure 2.4B). 
 Of importance to the apoptotic phenotype, a pathway identified to be 
significantly up-regulated in the P81S teratomas, but not in WT and R167Q 
teratomas, was mitochondrial biogenesis (Figure 2.7B). Mitochondrial biogenesis 
is characterized by the up-regulation of Ppargc1a (peroxisome proliferator 
gamma coactivatior-1 transcription factor) and downstream targets such as mtTfa 
and Creb [20]. Biogenesis signaling increases mitochondrial proliferation in 
response to environmental stress [21]. Cancer cells often up-regulate this 
intrinsic stress response system during tumor hypoxia or oxidative stress to avoid 
apoptotic signals and aid in survival [22]. The data suggest that the P81S 
mutants may have the ability to alter the intrinsic stress response to avoid 
apoptosis through the up-regulation of mitochondrial biogenesis, a hallmark of 
many cancer cell types. This hypothesis is currently under validation using 
additional biochemical measurements. 
E. Discussion 
 Since the identification of the TCE-associated P81S mutation over a 
decade ago, the disease relevance of this mutation in the alteration of VHL tumor 
suppressor gene function has gone unexplored. The lack of an animal model with 
which to study the role of VHL mutations in the initiation and progression of renal 
carcinogenesis has hindered this assessment [12]. In the present study, we have 
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utilized a novel mouse embryonic stem cell model system [9] and transcriptomics 
to characterize cells expressing the P81S pVHL mutant in comparison to cells 
expressing wild-type pVHL, as well as missense mutant R167Q pVHL, a 
mutation subtype which predisposes to renal cancer [9]. Through this 
comparison, we were able to show that the P81S mutant behaves similarly to the 
R167Q mutant in the E3-complex formation and dysregulation of HIF. However, 
unique to P81S was an anti-apoptotic phenotype which allowed the teratomas to 
grow exponentially faster. This lack of a balance between proliferation and 
apoptosis is characteristic of an aberrant phenotype as one might find in the 
transformation of cancer cells [22]. We have suggested that the upregulation of 
mitochondrial biogenesis may be a survival mechanism to avoid apoptotic signals 
due to the intrinsic stress response. 
 Dysregulated proliferation alone is not sufficient for tumor promotion, but 
also requires the support of anti-apoptotic signals [23]. This finding has been 
observed in studies where oncogene overexpression actually sensitized the cells 
to apoptosis, rather than growth, and suggests that either inactivation of pro-
apoptotic signals or expression of anti-apoptotic signals would be additionally 
required for progression [24]. In addition, in vitro and in vivo studies where pVHL 
had been acutely inactivated also found that this inactivation resulted in a 
senescent-like phenotype that was independent of p53 and HIF, but dependent 
on Rb inactivation and upregulation of p27 [25]. These studies suggest that when 
cells are faced with inactivation of pVHL, tumor suppressive mechanisms prevent 
further progression. In our study, the P81S mutation in VHL did not result in 
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protein inactivity or loss of translation, but rather suppressed the normal 
apoptotic signals required for growth regulation. It is unclear from this evaluation 
if the apoptotic affect was due to a HIF-dependent or a HIF-independent evasion 
pathway through mitochondrial biogenesis, as HIFs play a dynamic role in 
regulating many cellular processes including mitochondrial respiration and 
response to oxidative stress [26, 27, 28].  
 There is not a clear understanding of how mitochondrial biogenesis leads 
to respiratory dysfunction, or vice versa, and the Warburg Effect. The Warburg 
Effect, or aerobic glycolysis, occurs when cancer cells convert glucose to lactic 
acid even when there is sufficient oxygen present [29]. This adaptive pro-survival 
response in cancer cells, while inefficient at producing ATP, allows these cells to 
suppress apoptosis signals through the upregulation of PI3K/Akt signaling [30]. 
Interestingly, to overcome the lack of ATP production, these cells may increase 
mitochondrial biogenesis as yet another adaptive response, which also plays an 
important role in mediating tumor hypoxia [31]. During conditions of tumor 
hypoxia, the upregulation of peroxisome proliferator-activated receptor-gamma 
coactivator 1 alpha (PGC-1alpha), which increases mitochondrial biogenesis, 
leads to increased expression of HIF-regulated genes through stabilization of HIF 
protein [32]. The relationship between the pVHL-Biogenesis-HIF axes is unclear, 
yet the missense mutation of VHL at codon 81 appears to result in a pro-survival 
phenotype, implicating mutant pVHL or its effector functions in promoting tumor 
growth. 
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 In the epidemiological studies linking VHL mutations to TCE exposure, 
there were tumors with multiple VHL mutations as well as many with only the 
single P81S mutation [1, 2]. Based on the evidence that can be obtained from an 
in vitro system, the P81S pVHL mutant has strong implications as an RCC 
disease mutation. Many of the shared characteristics that describe the R167Q 
mutant, which confers a high risker for RCC, also apply to the P81S mutant. Our 
most striking finding was the anti-apoptotic phenotype, which was unique to this 
missense mutation, and allowed the promotion of teratocarcinoma growth by 
either suppressing or averting apoptotic signals. While the mechanism is yet 
unclear, this investigation into the P81S VHL mutation strongly suggests that 
certain mutations in VHL tumor suppressor gene may allow it to function in both 
the initiation and promotion of tumorigenesis. 
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Figure 2.1 
 
 Site Directed Mutagenesis of pVHL cDNA 
 
Sequencing of pBluescript II construct containing VHL cDNA to confirm CCG > TCG point 
mutation at C454T of the VHL gene.  Site-directed mutagenesis was performed on the 
pBluescript II construct harboring wild-type VHL cDNA to induce a missense mutation at 
codon 81 changing the amino acid from proline to serine. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
P81S VHL
wild-type VHL
 50 
 
Figure 2.2 
 
Effect of P81S VHL Mutation of E3-complex Formation and Function 
 
Co-immunoprecipitation of HA-pVHL and associated E3-complex members in transgenic ES 
cell clones (A) and Western Blot analysis of HIF1a Stabilization during normoxic and hypoxic 
condtions (B). Stably-transfected Vhl−/− murine ES cells expressing wild-type HA-pVHL or 
mutant HA-pVHL were grown under normoxic conditions till 70% confluency, lysed under 
non-denaturing conditions and subject to co-immunoprecipitation with an antibody against 
the HA-tag. Anti-HA IP products were probed for successful pull-down of WT or mutant HA-
pVHL and for co-IP of the E3-complex members Elongin C and Cullin2 (A). Whole-cell 
protein extracts were prepared from stably-transfected Vhl−/− murine ES cells expressing 
wild-type HA-pVHL or mutant HA-pVHL under normoxic and hypoxic conditions using 
100uM CoCl2 as a hypoxia mimic. Western blot shows HIF1a (*upper band) and loading 
control (B). 
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Figure 2.3 
 
P81S VHL Mutant Displays Growth Advantage and Differentiation In Vivo 
 
In vivo teratoma assay grown from ES cell clones. Stably-transfected Vhl−/− murine ES cells 
expressing wild-type, P81S or R167Q pVHL were injected subcutaneously into the flank 
region of nude mice and allowed to grow for 4 weeks. Mice were sacrificed and teratomas 
removed, measured and photographed (A). Tumor volume was measured weekly using 
calipers (B). Hematoxylin and eosin staining of teratomas (C) shows areas of differentiation 
and vasculature, as indicated by a black arrow.   
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Figure 2.4 
 
Effect of P81S Mutation on In Vivo HIF Stability and Transcriptional Activity  
 
Immunoblot of HIF2 protein in ES cell pVHL teratomas (A) and HIF target gene expression 
by qRT-PCR (B). Stably-transfected Vhl−/− murine ES cells expressing wild-type, P81S or 
R167Q pVHL were injected subcutaneously into the flank region of nude mice and allowed 
to grow for 4 weeks. Teratomas were removed and either (A) whole cell lysates prepared for 
immunoblotting for HIF2 protein and loading control beta-tubulin, or (B) RNA was extracted 
and qRT-PCR was performed on HIF targets (glucose transporter; Glut1, vascular 
endothelial growth factor; Vegf, erythropoietin; Epo and phosphofructokinase; Pfk) to 
examine gene expression. Statistical analysis by ANOVA *p≤0.05. 
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Figure 2.5 
 
Effect of the P81S VHL Mutation on Teratoma Proliferation and Apoptosis 
 
Immunohistochemistry of proliferation (A,B) and apoptosis (C,D) markers in ES cell pVHL 
teratomas. Stably-transfected Vhl−/− murine ES cells expressing wild-type, P81S or R167Q 
pVHL were injected subcutaneously into the flank region of nude mice and allowed to grow 
for 4 weeks. Teratomas were removed, paraffin-embedded and sectioned for 
immunohistochemical analysis. 5uM sections were stained with proliferation marker Ki67 (A) 
or apoptosis (C) Quantification of percent positive cells for each mutant was performed (B, 
D). N = 4 with 5-6 sections scored. Statistical significance by ANOVA, *p≤0.05.  
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Figure 2.6 
 
Unsupervised Hierarchical Clustering of ES Cell Teratomas 
 
Hierarchical clustering of ES cell teratomas for differentially expressed genes. Stably-
transfected Vhl−/− murine ES cells expressing wild-type, P81S or R167Q pVHL were injected 
subcutaneously into the flank region of nude mice and allowed to grow for 4 weeks. RNA 
was isolated and used to perform microarray analysis using the Affymetrix Mouse Gene ST 
1.0 whole genome array. Differentially expressed genes were determined using Partek® 
Genomics Suite. Statistical significance by ANOVA with a FDR = 5%, *p≤0.001. Gene list of 
2,622 genes was then clustered unsupervised by expression. Red – upregulated, Blue- 
downregulated. 
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Figure 2.7 
 
Clustering and Biological Pathway Analysis of P81S Teratomas 
 
Hierarchical clustering of P81S and WT ES cell teratomas for differentially expressed genes. 
Stably-transfected Vhl−/− murine ES cells expressing wild-type, P81S pVHL were injected 
subcutaneously into the flank region of nude mice and allowed to grow for 4 weeks. RNA 
was isolated from 4 replicate P81S and 3 replicate WT teratomas, and used to perform 
microarray analysis using the Affymetrix Mouse Gene ST 1.0 whole genome array. 
Differentially expressed genes were determined using Partek by two-sample t-test, p≤0.001. 
Gene list was clustered unsupervised by expression (A). Biological pathway analysis was 
performed on genes that were differentially upregulated by either WT or P81S teratomas 
(B). Red – upregulated, Blue- downregulated  
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Chapter Three: 
DIETARY FATTY ACIDS AND MICRONUTRIENTS MODULATE LOW DOSE 
ARSENIC-INDUCED KIDNEY TOXICITY AND GENE EXPRESSION  
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A. Abstract 
 Inorganic arsenic is a common co-contaminant in both food and water 
sources worldwide, and is thought to contribute to the increased risk of kidney 
cancer. Dietary fat and micronutrients have been shown to profoundly affect 
genomic and toxicological studies, implicating a role for nutritional status in 
disease outcome. Given the increase in obesity and poor diet in the U.S., the role 
of dietary fatty acids and micronutrients has not been adequately considered in 
genomic studies of inorganic arsenic.  In this study, we compared arsenic-
induced gene expression changes in the kidney between mice fed either a 
standard purified lab chow or a high fat western diet.  Male and female FVB/N-
Abcb1a/1b-/- (Mdr-/-) knockout mice were divided into 6 groups (n=6) with free 
access to either a standard fat (7% fat) or western diet (34% fat) containing 0, 10, 
or 150ug/kg sodium arsenite for 10 weeks. At sacrifice, kidneys were removed 
for histopathological examination as well as examined for changes in gene 
expression. Subchronic exposure to low dose arsenic on a high fat western diet 
significantly reduced kidney weights and increased serum lactate dehydrogenase 
with arsenic exposure. This effect was not seen with arsenic exposure on a low 
fat diet. Microarray analysis of the kidneys revealed a clear dose-response 
signature in both diets. Moreover, diet had a significant effect on the type of 
signaling pathways altered by arsenic exposure. The results indicate that arsenic 
exposure in the context of a high fat diet can induce signaling pathways 
commonly overexpressed in most human kidney tumors, and further suggests 
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that dietary composition may play a critical role in modifying toxicity to low dose 
arsenic in chronic studies. 
B. Introduction 
 Inorganic arsenic is a global water and food contaminant and is 
associated with the development of kidney cancer in susceptible human 
populations [1]. The nutritional state of an individual is known to modify 
susceptibility to toxicity and disease risk [2]. This is especially true in the case of 
inorganic arsenic, where essential nutrients are important co-factors in the 
metabolism and detoxification of arsenic [3]. Given the variability in nutritional 
intake among human populations, there are significant gaps in toxicological 
studies examining the role of dietary fat and micronutrients in the modulation of 
renal toxicity due to arsenic exposure. Since standard rodent chow diets are 
balanced for optimal nutrition, it seems critical to examine arsenic toxicity in the 
context of altered nutritional intake to explore the role of diet in the development 
of arsenic-induced disease pathologies. 
 The amount and type of dietary fat is known to alter a variety of 
physiological and pathophysiological functions critical to the outcome of 
toxicological studies [4]. ω-6 and ω-3 polyunsaturated fatty acids (PUFAs), which 
are derived from animal and plant based lipids, have been shown to induce a 
pro-oxidant state within cellular compartments when their intake ratios are 
imbalanced [5,]. These two types of fatty acids compete directly with one another 
for incorporation into cellular compartments, where they can influence cell 
signaling pathways and receptor function [6]. In the U.S. the ω-6 to ω-3 intake 
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ratio of PUFAs has changed dramatically from an average 7:1 to an imbalanced 
ratio of 15:1 [7]. This change is likely due to an increased consumption of highly 
processed foods, and a decreased consumption of fresh fish and natural oils. 
Despite this shift in dietary intake, it remains undetermined how an imbalanced 
ratio of PUFAs modulate susceptibility to arsenic-induced renal toxicity. 
 Essential micronutrients obtained through diet play a direct role in arsenic 
metabolism and toxicity. Micronutrients such as methionine, folic acid and choline 
interact with arsenic by altering its binding to target proteins, metabolism and 
tissue retention [8]. Diets deficient in folic acid have been shown to reduce the 
urinary elimination of arsenic metabolites, allowing increased tissue retention [9]. 
Additionally, diets low in choline and methionine decrease levels of S-
adenosylmethionine, a universal methyl donor, which reduces the detoxification 
of arsenic as well as alters the normal methylation of DNA resulting in epigenetic 
alterations [10]. We can infer that individuals consuming a diet deficient in 
micronutrients may be predisposed to arsenic-induced renal toxicity and 
epigenetic alterations in gene expression.  
 The average American adult ingests less than 10µg inorganic arsenic per 
day, however this varies greatly by lifestyle and environmental exposures though 
groundwater, grains, and cigarette smoke [11]. The increased rate of metabolism 
and elimination of arsenic in mice hinders the examination of low doses, relevant 
to human exposure [12]. This has greatly hampered our ability to explore the role 
of diet arsenic-induced toxicity. Recently, the use of knockout or humanized 
mouse models has captured the inherent species differences in the metabolism, 
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distribution, and excretion of inorganic arsenic that is under genetic control [13, 
14]. The multi-drug resistant transporter knockout mouse (Mdrb1a/1b-/-) 
accumulates arsenic within the mouse kidney as well as other tissues, mimicking 
the delay in elimination of arsenic in humans [14]. These models have proven 
effective in generating organ-specific arsenic toxicity due to sequestration. In this 
study, we evaluated the role of dietary fat and micronutrients following a 
subchronic exposure to inorganic arsenic at environmentally-relevant doses 
using the Mdr-/- knockout mouse. Kidney gene expression patterns and pathway 
analysis reveal both a dose- and diet-dependent role in modulating cellular 
response to inorganic arsenic. 
C. Methods 
Animals and treatments.  
All animal studies were conducted in accordance with AALAC approved 
guidelines using a protocol approved by IACUC at North Carolina State 
University Biological Resources Facility. At six to eight-weeks of age FVB/N-
Abcb1a/1b-/- knockout mice (Taconic, Rockville MD) were randomly assigned to 
either a custom purified high fat western diet, low in choline and folate (HFD) or 
standard low fat AIN-93M chow (LFD) that had been specially formulated for this 
study by the manufacturer with the addition of 0, 10 or 150ug/kg sodium arsenite 
(Harlan Teklad, Madison, WI). Mice were acclimated to the HFD or LFD for 2 
weeks prior to initiation of the iAs study to allow for washout of residual diet. Male 
and female mice were housed in same-sex cages, 3 mice per cage, with ad 
libitum access to food and water. To preserve quality, all diets were kept in 
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refrigerated, vacuum sealed-pouches, and were replaced biweekly. Animals were 
weighed and euthanized using a single overdose injection of Avertin anesthetic. 
Serum was collected for routine clinical chemistry. Kidneys were removed, 
weighed, and either fixed in 10% neutral buffered formalin solution for histological 
sections or flash frozen and stored at −80 °C for molecular analyses.  
RNA isolation.  
Frozen kidney samples were homogenized using a tissue bead-lyser and 
RNA isolated using RNeasy® Mini Kits (Qiagen, Valencia, CA) per 
manufacturer's protocol. Total RNA was quantified with a NanoDrop®ND-1000 
Spectrophotometer (NanoDrop Technologies, Rockland, DE). RNA quality was 
determined with the Agilent Bioanalyzer (Agilent Technologies, Inc., Santa Clara, 
CA). 
Microarray analysis.  
 Microarray experiments were performed using GeneChip® Mouse ST 
Gene 1.0 whole genome arrays from Affymetrix (Santa Clara, CA) at the UNC 
Genomics Core Facility. Total RNA samples were processed following a 
standard one-cycle eukaryotic target preparation protocol from Affymetrix. Briefly, 
total RNA was first reverse-transcribed using T7-oligo(dT) promoter primer in the 
first-strand cDNA synthesis reaction. Following second-strand cDNA synthesis, 
the double stranded cDNA was purified and served as a template in the 
subsequent in vitro transcription (IVT) reaction. The IVT reaction was carried out 
in the presence of T7 RNA Polymerase and a biotinylated nucleotide 
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analog/ribonucleotide mix for complementary RNA (cRNA) amplification and 
biotin labeling. Biotinylated cRNA targets were then purified, fragmented, and 
hybridized to array during the overnight incubation at 45°C in a rotating 
hybridization oven. After hybridization, the arrays were stained with streptavidin-
phycoerythrin in the GeneChip® Fluidics station and then scanned using 
Affymetrix GeneChip® Scanner (laser filter set at 570 nm; pixel size 2.5 μm). The 
array image data were acquired, and the fluorescent signal intensities were 
quantified using Affymetrix® GCOS software with following settings of 
quantitation parameters: Alpha1 = 0.05, Alpha2 = 0.065, Tau = 0.015, Gamma1H 
= 0.0045, Gamma1L = 0.0045, Gamma2H = 0.006, Gamma2L = 0.006, 
Perturbation = 1.1, Target Intensity = 150. 
Pathway analysis and statistics. 
The Affymetrix Mouse ST Gene 1.0 array has approximately 27 probes 
spread across each of the 28,853 genes represented on the array, providing a 
more complete and more accurate picture of gene expression than 3'-based 
expression array designs. The sequences from which the array probe sets were 
derived from GenBank®, Ensembl, dbEST, and RefSeq. Gene expression data 
(CEL files) were analyzed using Partek® Genomic Suite, version 6.3 (Partek Inc., 
St. Louis MO). Gene expression data were normalized by robust multi-array 
analysis (RMA) and analysis of variance was performed using Partek® software. 
We identified differentially expressed genes between classes using the non-
parametric rank-product method (p-value <0.05 and 0.01) and log2 expression 
values for each gene were generated. Canonical pathway analysis was 
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generated through the use of Ingenuity Pathways Analysis (IPA) (Ingenuity® 
Systems, www.ingenuity.com). Canonical pathway analysis was measured in two 
ways: (1) a ratio of the number of genes from the data set that map to the 
pathway divided by the total number of genes that map to the canonical pathway, 
and (2) Fischer's exact test to calculate a p-value.  
D. Results 
High fat diet exacerbates kidney toxicity due to arsenic exposure. 
 Male and female Mdrb1a/1b-/- knockout mice were divided into 6 groups 
(n=6) with free access to either AIN-93M (10%) or Americanized high fat (34% 
fat) chow containing 0, 10, or 150ug/kg sodium arsenite for 10 weeks. At 
sacrifice, kidneys were removed, weighed and sectioned for histopathological 
examination. Food intake of the mice was not affected by the type of diet or by 
dose of arsenic (data not shown). While overall kidney morphology was 
unchanged between diets and doses, kidney to body weight ratios (Figure 3.1B) 
significantly decreased in mice fed a low dose of arsenic on a high fat, 
micronutrient poor diet. The mice fed a high fat diet given a low dose of arsenic 
for 10 weeks lost nearly one-third of their kidney weight over control animals by 
10 weeks. In addition, serum lactate dehydrogenase, a general marker of tissue 
injury, was significantly increased in the HFD-fed mice with arsenic (Figure 3.1A). 
This effect was consistent across sexes but was not observed in LFD-fed mice 
treated with arsenic. This indicates that a high fat, micronutrient poor diet 
increases kidney-specific organ toxicity. 
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High fat diet alone increased genes involved in fatty acid metabolism and 
arsenic metabolism. 
 We performed full genome array analysis on the kidney tissues of male 
and female Mdr-/- knockout mice given either LFD or HFD alone for 10 weeks to 
investigate the gene expression changes that would occur due to diet alone. We 
performed a two sample t-test to identify differentially expressed genes (p<0.05) 
between the two control groups and identified 1408 genes (Figure 3.2A). Of 
them, 797 genes were specifically upregulated in the HFD-fed mice. Canonical 
pathway analysis of upregulated genes of high fat diet treated mice revealed 
expression of genes involved in fatty acid metabolism (Acyl-Co synthase: Acsl6, 
aldo-keto reductases: AKR1A1, AKR1C1) and Cytochrome p450-xenobiotic 
metabolism of sterols such as cholesterol (Cyp11a1, Cyp17a1, Cyp2b13, 
Cyp2c44, Cyp2d13,Cyp2s1, Cyp3a43) (Figure 3.2B).  We also found a significant 
upregulation of Gsto2 (glutathione-s-transferase omega 2) which is involved in 
glutathione conjugation during arsenic metabolism [15]. Several polymorphisms 
in the Gsto2 gene have been associated with increased urothelial cancer risk due 
to arsenic exposure [16]. This suggests that a high fat diet alone increases the 
expression of arsenic metabolism genes which may increase its metabolism and 
toxicity in situ. 
Hierarchical clustering reveals a diet effect on low dose exposures. 
 To understand how this diet-induced change in baseline gene expression 
would affect the same exposure-level to inorganic arsenic, we first performed 
unsupervised hierarchical clustering of the low dose groups with their respective 
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control groups (low fat and high fat). As seen in Figure 3.3A, a multiple 
comparisons ANOVA with FDR of less than 5%, found 1365 genes differentially 
expressed by diet and dose. Clustering analysis was performed on this gene set, 
and the dendrogram shows that the samples segregated based on dietary 
treatment. This suggests that the dietary composition is able to alter the types of 
genes expressed during a response to low dose arsenic exposure.  
 To further examine the gene clusters identified, we performed a two 
sample t-test on each low dose group compared to their respective diet control. 
Exposure to a low dose of arsenic on a LFD significantly induced 695 genes, 
whereas the same dose on a HFD induced 833 genes (p<0.05). Canonical 
pathway analysis on both genes sets showed that fibroblast growth factor 
signaling, steroid biosynthesis and PTEN signaling were upregulated on a LFD, 
while mitochondrial dysfunction, AMPK signaling, Type II diabetes mellitus 
signaling (Pparg, Adipo, Akt) and NRF2-mediated oxidative stress were induced 
in mice fed a HFD (Figure 3.3B). Together this suggests that renal cells from 
mice fed a LFD respond to low dose arsenic by increasing angiogenesis, growth, 
apoptosis and biosynthesis, while mice on a HFD have a more aberrant 
response of mitochondrial dysfunction, compensatory AMPK signaling to account 
for the loss of ATP, increased oxidative stress and upregulation of genes 
involved in insulin resistance. 
Dose-response signatures evident on both diets. 
 To compare the dose-response signatures across both diets, we 
performed an unsupervised clustering of the control, low dose, and high dose 
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groups on each of their respective diets. (Figure 3.4A and B) We performed 
analysis of variance (p<0.05) and found 1297 genes differentially expressed by 
dose on a LFD (Figure 3.4A) and 1505 genes differentially expressed by dose on 
a HFD (Figure 3.4B). The dendrograms indicate a clear dose-response gene 
expression signature for all doses on both diet backgrounds, suggesting that 
even at low environmentally-relevant doses of inorganic arsenic exposure, a 
unique expression pattern can characterize the magnitude of exposure. This 
confirms the use of gene expression analysis in the evaluation of 
environmentally-relevant exposures to inorganic arsenic.  
Upregulation of cancer-related pathways in high fat fed mice.  
 To examine the effect of high dose arsenic compared to their respective 
dietary controls, we performed two-sample t-test (p<0.05). We identified 565 
genes differentially expressed by high dose arsenic on LFD and 902 genes on a 
HFD. Canonical pathway analysis (Figure 3.4C) revealed bladder cancer 
signaling, colorectal cancer metastasis signaling, CREB signaling and RXR 
activation were induced in mice given a high dose of arsenic on a HFD 
background. In contrast, mitochondrial dysfunction, cholesterol metabolism, RXR 
activation and cytochrome p450 metabolism of steroids were induced on a LFD 
background. Interestingly, the LFD + high dose pathways closely overlap with the 
HFD alone without arsenic exposure suggesting that metabolic perturbations 
may be playing a role in the altered gene expression. The upregulation of genes 
associated with cancer-related pathways was only observed in HFD fed mice, 
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and suggests that altered dietary fats and micronutrient deficiency exacerbates 
arsenic toxicity on the kidney.  
E. Discussion  
 The standard of practice for inorganic arsenic administration in laboratory 
mouse experiments ranges from 1 to 50 ppm in drinking water, which is several 
thousand-fold greater than the average daily intake for an American adult [17, 
18]. In addition, a nutritionally poor diet, high in ω-6 PUFA, refined sugars, and 
vitamin deficiency, is well known to contribute to the rising incidence of obesity 
and cancer in the U.S. [19]. However, little attention has been given to the 
nutritionally poor as a susceptible population in toxicological studies of arsenic 
exposure. In this study, we have evaluated the role of dietary fatty acids and 
micronutrients in arsenic-induced kidney gene expression changes following a 
subchronic exposure to environmentally-relevant doses of inorganic arsenic 
using the Mdr-/- knockout mouse. Kidney gene expression patterns and pathway 
analysis reveal both a dose- and diet-dependent role in modulating renal toxicity 
and response to inorganic arsenic. Importantly, we found that altering the diet 
composition to mimic human consumption of vitamins and dietary fats, was able 
to increase several cancer-related signaling pathways in the kidney. 
 Reducing dietary folic acid in the Americanized HFD diet has mechanistic 
ties to increasing arsenic toxicity. Much of what we currently know about the 
nutritional epigenetics of arsenic is that human susceptibility to certain arsenic-
related cancers is modified by dietary folate intake [20]. Folate plays an essential 
role in one-carbon metabolism and production of S-adenosylmethionine (SAM), 
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the primary methyl group donor for most biological methylation reactions [10]. 
DNA methylation is an important epigenetic determinant in gene expression, in 
the maintenance of DNA integrity and stability, chromosomal modifications, and 
in the development of mutations [10]. Aberrant patterns and dysregulation of 
DNA methylation at CpG islands are mechanistically related to the development 
of renal carcinogenesis through the silencing or mutation of key tumor 
suppressor genes such as the VHL tumor suppressor gene [21]. This suggests 
that a potential mechanism of altered gene expression in this study may be due, 
in part, to epigenetic changes.   
 We found that a folate reduced-high fat diet, without arsenic, induced the 
basal expression of Gsto2, glutathione-S-transferase omega 2, which conjugates 
arsenic to glutathione prior to methylation by SAM [15]. In human studies, 
polymorphisms in GSTO2 that increase transferase activity showed a positive 
correlation to renal cancer risk [22]. We can infer then that driving the conjugation 
and subsequent methylation of arsenic increases arsenic toxicity. Several studies 
examining the methylated metabolites of arsenic agree that the metabolism of 
arsenic increases its toxicity in vitro and in vivo [23, 24]. This has been 
postulated to occur though several mechanisms: SAM depletion and epigenetic 
alterations, a direct interaction of methylated arsenic with proteins, as well as an 
indirect mechanism of inhibition of DNA repair [25]. Certainly, the limitation of 
gene expression data is that without mechanistic studies, it is impossible to know 
if the rate of metabolism of arsenic was increased in our HFD treated mice. It 
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does suggest, however, that dietary factors could be playing a role in increasing 
tissue susceptibility through the upregulation of arsenic metabolism genes. 
 We also found that the administration of arsenic on the HFD background 
was able to increase mammalian target of rapamycin (mTOR) signaling, a 
signaling pathway commonly dysregulated in renal cell carcinoma [26]. mTOR 
plays an important role in cellular growth, differentiation, angiogenesis, and 
regulation of mitogenesis, and is thought to act as a nutrient and environmental 
sensor [27]. mTOR has been shown to increase hypoxia inducible factor (HIF1) 
levels and promote angiogenesis through the expression of vascular endothelial 
growth factor (VEGF) [28, 29]. In several studies examining arsenic-induced 
alterations in gene expression using human cell lines, HIF1α, VEGF and STAT1 
were all upregulated in response to arsenic exposure [29, 30], suggesting that 
mTOR may be a central player. While our results are consistent with the data 
obtained from human cells lines, this report is the first to show this effect though 
an in vivo exposure in the mouse kidney, suggesting that both dietary 
modifications and low dose exposure is a valid approach to study the effects of 
chronic arsenic exposure on kidney toxicity. 
 Oxidative stress and mitochondrial dysfunction have also been shown to 
mediate the cytotoxic effects of arsenic [31]. Inorganic arsenic competes with 
molecular phosphate, which can perturb the production of ATP and affect the 
mitochondria [31]. In our pathway analysis, NRF2-mediated oxidative stress was 
found to be upregulated with arsenic exposure, and suggests a pro-oxidant state 
may be induced with arsenic exposure [32]. In vivo experiments have shown that 
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folic acid supplementation can alleviate this toxicity by reducing oxidative stress 
generated by free radicals [33]. Our results showed that a folate reduced-high fat 
diet can exacerbate oxidative stress by lowering the dose of arsenic necessary to 
see such an effect, implicating a dietary role in the toxicity of arsenic at very low 
doses. 
 Nutritional state as a modifier of susceptibility has been clearly described 
in human epidemiological studies as well as in several mouse models of cancer 
susceptibility [34, 35]. However, nutritional state is rarely accounted for in 
toxicological studies in rodents. In this study we have shown that a nutritionally 
poor diet alters tissue response to inorganic arsenic and has revealed an 
increase in cancer-related signaling pathways. Such modifications were 
observed not only at environmentally-relevant doses, but also in the appropriate 
target tissue which aids to strengthen the utility of mechanistic studies of chronic 
exposure and the translation to human relevance.  
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Figure 3.1 
 
Arsenic Dose and Diet Effect on LDH and Kidney Weight 
 
FVB Mdr-/- knockout mice were divided into 6 groups (N = 6) with free access to either AIN-
93 (low fat diet) or an Americanized (high fat diet) chow containing 0, 10, or 150ug/kg  
(control, low dose, high dose) sodium arsenite for 10 weeks. Serum was analyzed for lactate 
dehydrogenase (LDH) as a measure of tissue injury (A). Kidneys were harvested and 
weighed and compared to body weights (B). Statistical Analysis by ANOVA compared to 
respective controls, *p≤0.05. 
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Figure 3.2 
 
Unsupervised Hierarchical Clustering of LFD and HFD-fed Mouse Kidneys 
 
Hierarchical clustering of LFD and HFD-fed mouse kidneys for differentially expressed 
genes. FVB Mdr-/- knockout mice were divided into 6 groups (N = 6) with free access to 
either AIN-93 (low fat diet) or an Americanized (high fat diet) chow containing 0, 10, or 
150ug/kg  (control, low dose, high dose) sodium arsenite for 10 weeks. RNA was isolated 
and used to perform microarray analysis using the Affymetrix Mouse Gene ST 1.0 whole 
genome array. Differentially expressed genes were determined using Partek® Genomics 
Suite. Statistical significance by t-test with a FDR = 5%, p≤0.05. Gene list of 1,408 genes 
was then clustered unsupervised by expression (A). Biological pathway analysis was 
performed on genes that were differentially upregulated in HFD (B). Red – upregulated, 
Blue- downregulated  
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Figure 3.3 
 
Effect of Diet on Gene Expression with Low Dose Arsenic Exposure 
 
Hierarchical clustering of Low Dose and Control (LFD and HFD) mouse kidneys for 
differentially expressed genes. FVB Mdr-/- knockout mice were divided into 4 groups (N = 3) 
with free access to either AIN-93 (low fat diet) or an Americanized (high fat diet) chow 
containing 0 or 10ug/kg  (control, low dose) sodium arsenite for 10 weeks. RNA was isolated 
and used to perform microarray analysis using the Affymetrix Mouse Gene ST 1.0 whole 
genome array. Differentially expressed genes were determined using Partek® Genomics 
Suite. Statistical significance by ANOVA with a FDR = 5%, p≤0.05. Gene lists were then 
clustered unsupervised by expression (A). Biological pathway analysis was performed on 
genes that were differentially upregulated by diet (B). Red – upregulated, Blue- 
downregulated  
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Figure 3.4 
 
Effect of Diet on Gene Expression with High Dose Arsenic Exposure 
 
Hierarchical clustering of differentially expressed genes in Control, Low and High Dose 
treated mice on either a LFD or HFD. FVB Mdr-/- knockout mice were divided into 6groups 
(N = 2-3) with free access to either AIN-93 (low fat diet) or an Americanized (high fat diet) 
chow containing 0, 10 or 150ug/kg  (control, low dose, high dose) sodium arsenite for 10 
weeks. RNA was isolated and used to perform microarray analysis using the Affymetrix 
Mouse Gene ST 1.0 whole genome array. Differentially expressed genes between control 
and high dose were determined using Partek® Genomics Suite. Statistical significance by 
two sample t-test with a FDR = 5%, p≤0.05. Gene lists were then clustered unsupervised by 
expression (A). Biological pathway analysis was performed on genes that were differentially 
upregulated by diet and dose (B). Red – upregulated, Blue- downregulated  
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Chapter Four: 
A POPULATION-LEVEL GENETIC MODEL REVEALS AN EARLY MARKER 
OF KIDNEY INJURY AND A GENETIC-BASIS FOR SUSCEPTIBILITY 
 83 
A. Abstract 
 Co-exposure to low levels of trichloroethylene (TCE) and inorganic arsenic 
(iAs) through groundwater and dietary contamination occurs in many localities 
and is thought to result in multiple organ toxicities in susceptible human 
populations. The interpretation of disease associations with TCE and iAs is under 
great debate in part due to the lack of an appropriate population-level 
experimental model with which to test the effect of inter-individual variation in 
metabolism, detoxification, and transport. To model the genetic heterogeneity of 
exposed human populations, we developed a unique intercross population 
derived from FVB/N-Abcb1a/1b-/-, a multi-drug resistant p-glycoprotein knockout 
mouse model, and CAST/EiJ a wild-derived strain that is genetically distinct from 
the FVB/N background. By modulating drug transport and genetic variation in the 
mouse to model human biology, including using a western diet, environmentally-
relevant doses of TCE and iAs can be evaluated for their effects on toxicity 
susceptibility. A study cohort of 900 FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 mice was 
divided into nine dose groups, each containing 50 female and 50 males, and was 
administered TCE and sodium arsenite via the drinking water and chow at 
environmentally-relevant concentrations for 52 weeks using a dose-ratio 
approach. We collected serum and urine for evaluation of biomarkers of kidney 
and other organ injury. Levels of classical biochemical markers serum alanine 
aminotransferase and blood urea nitrogen showed no significant differences at 
16 weeks. However, urinary neutrophil gelatinase-associated lipocalin-2, a 
sensitive biomarker of early renal injury, was increased 3- to 7-fold over controls 
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at week 16 in mice treated with both TCE and iAs. This data suggests that TCE 
and iAs may cooperate to produce renal toxicity that may be modulated by 
genetic determinants. 
B. Introduction  
 Human exposure to environmental carcinogens often occurs as complex 
mixtures at low doses, and such interactions between individual compounds may 
contribute significantly towards human cancer risk [1]. Trichloroethylene (TCE) 
and inorganic arsenic (iAs) are suspect kidney carcinogens commonly found in 
contaminated drinking water worldwide [1]. Although epidemiological evidence 
shows an association between dietary exposures and an increased risk for 
kidney cancer in humans [2], animal models of TCE or iAs-induced kidney 
toxicity and carcinogenesis have been largely absent [3]. Further, few efforts 
have addressed potential modifiers of response such as species-differences in 
drug metabolism and transport, and nutritional status that play roles in an 
individual’s response to kidney toxicants at low doses. This lack of biologically-
based models has hindered both mechanistic studies as well as identification of 
biomarkers of effect that have clinical translation.  
 The genetic basis of susceptibility to environmental carcinogens has been 
well established in human populations, but remains poorly modeled in 
toxicological studies. Inbred mouse lines provide a fixed genotype within a 
particular strain and capture an enormous genetic diversity across strains due to 
the number and distribution of genetic polymorphisms [4]. As such, inbred mouse 
diversity panels have recently been exploited in toxicological studies for the 
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determination of susceptible and resistant strains as well as identification of 
biomarker genes whose expression strongly correlates with toxicity [5]. However, 
the identification of genetic loci that both control and modify a specific trait, i.e. 
susceptibility to kidney injury, requires a mapping population obtained through 
controlled crosses [6].  
 The development of a population-based genetic model for use in the 
identification of susceptibility genes requires selection of parental strains that 
exhibit variation at the DNA sequence and phenotype levels [6]. In this study, we 
examined the hypothesized mechanisms of cytotoxicity for TCE and iAs as a 
basis for selecting critical genes of interest that may modify the resulting toxicity 
phenotype. We then examined the kidney gene expression of DNA repair 
enzymes Ogg1 as well as drug transporters Abcb1a/1b across 37 inbred strains 
to identify two strains with differential expression, in addition to extensive 
polymorphic variants. Here, we developed a unique F3 mouse population derived 
from FVB/N-Abcb1a/1b-/- mice, a multidrug resistant ABC transporter knockout, 
and CAST/EiJ a wild-derived strain from a different subspecies of Mus musculus. 
The Mdr-/- mice show decreased clearance of drug metabolites, including 
arsenic, and are more susceptible to injury in the kidney [7], while CAST/EiJ 
allows us to examine genetic variability as this strain carries a completely 
different set of allele combinations, including VHL. In the present study, we 
hypothesized that co-exposure to TCE and iAs will act in an additive fashion to 
induce renal toxicity and that the use of an F3 mouse population model will reveal 
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a genetic basis for renal toxicity due to environmentally-relevant dose mixtures of 
trichloroethylene and inorganic arsenic.  
C. Methods 
Mouse population generation and design.  
All breeding was performed in house at North Carolina State University 
Biological Resource Facility. Female FVB/N-Abcb1a/1b-/- knockout mice 
(Taconic, Rockville MD) and male CAST/EiJ (Jackson Laboratory, Bar Harbor 
ME) were intercrossed for three generations to generate a population of nine 
hundred FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 mice. To avoid litter effects in the 
study, mice were weaned to one of nine dose groups, with one same-sex pup per 
litter per group at 3 weeks of age. Maximum litter size never exceeded more than 
9 pups of each gender. Each same-sex cage contained 10 mice, which remained 
together throughout the duration of the study. Each of nine dose groups included 
100 mice (50 females and 50 males). At 6 weeks, mice were switched from the 
purified AIN-93G diet (Harlen Teklad, Madison WI) to a custom purified high fat 
Americanized diet (Harlen Teklad, Madison WI) (Table 4.1) and were allowed to 
acclimate for 2 weeks before entering the study. We staggered entry dates for F3 
mice from all crosses, to minimize any confounding by calendar time of 
procedures.  Approximately 200-300 F3 mice entered the study protocol every 
four to five weeks over a 16-week window. Furthermore, all sample collections 
were performed within narrow time windows during the day to minimize the 
impact of circadian effects on the data. 
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Dietary treatment: a dose-ratio approach.  
 Dose-equivalent quantitation was used to determine dosage. 
Trichloroethylene and inorganic arsenic were added to the drinking water and 
chow, respectively, at environmentally relevant concentrations (Figure 4.1). A low 
and high dose for each compound was selected to be no more than 2 to 6-fold 
greater than an actual human exposure dose-equivalent. To incorporate an 
assessment of a two-compound mixture as well as a dose-response, a dose-ratio 
approach was used to form nine dose groups (Figure 4.2).   
 Nine hundred FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 mice were assigned to 
one of nine dosing groups at weaning as described above. At 6 weeks, all mice 
were acclimated to the custom high fat Americanized diet for 10-14 days before a 
baseline serum and urine measurement was collected from each animal. Mice 
were then switched to Nanopure drinking water containing 0, 5, or 2850ppb TCE 
and a custom high fat chow with the addition of 0, 10 or 150µg sodium arsenite 
per kilogram diet. To preserve freshness and minimize degradation, TCE water 
was prepared fresh, replaced weekly and administered in UV-light protected 
water bottles. Arsenic containing chow was kept in vacuum-sealed refrigerated 
pouches and replaced weekly. Animals remained on this custom dietary 
treatment for the duration of the 52 week study.     
Serum collection.  
 For evaluation of biochemical markers of tissue injury, whole blood was 
collected at week 0, 16, 32 and 52 using the submandibular bleed method. 
Briefly, a 5mm lancet (GoldenRod, Mineola NY) was used to puncture the 
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submandibular vein and whole blood was collected in EDTA-free capillary tubes 
(Sarstedt, Newton NC). Blood was allowed to coagulate 30min at room 
temperature before being centrifuged at 10,000 x g for 20min. The serum layer 
was placed into a clean 1.5mL tube and stored at -80°C until future analysis. All 
serum collections were performed in the morning hours, within a narrow time 
window to minimize the impact of circadian effects on the data.  
Urine collection.  
 Urine was collected at week 0, 16, 32, and 52 for endpoints such as 
arsenic metabolite measurement, NMR-based metabolomics and evaluation of 
urinary biomarkers. Briefly, mice were individually housed in custom-designed 
metabolic cages (Hatteras Instruments Inc., Cary NC) for 16 hours with ad libitum 
access to drinking water only. Each cage collects the freshly voided urine using a 
stainless steel funnel to channel the urine, and not feces, into a chilled 2mL 
collection tube, maintaining the urine sample at 34° to 42°C. Urine samples were 
then placed on ice while color, clarity and volume were recorded. Samples were 
stored at -80°C until future analysis. 
Clinical chemistry.  
 Measurement of serum alanine aminotransferase and blood urea nitrogen 
as biochemical markers of tissue injury was performed at the UNC Animal 
Pathology Clinical Chemistry Core Facility. Results are reported as mean ± 
standard error with n = 20-30 in each group. Treatment groups were compared 
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using one-way ANOVA analysis. A p<0.05 was selected before the study to 
determine statistical differences between groups. 
NGAL ELISA.  
 Neutrophil gelatinase-associated lipocalin (NGAL) was measured in urine 
samples by ELISA assay as a marker of early renal injury (R&D Systems, 
Minneapolis MN). Urine samples were thawed on ice and an aliquot removed, 
centrifuged and diluted 1:10 in the provided assay buffer. The assay was 
performed per manufacturer’s protocol. Samples were measured in duplicate 
using a microplate reader set at 540nm/450nm within 30min of addition of stop 
buffer. Concentrations of NGAL were determined based on a standard curve. 
Results are reported as mean ± standard error with n = 20-30 in each group. 
Treatment groups were compared using one-way ANOVA analysis followed by 
Tukey’s multiple comparison post-hoc test, where appropriate. A p<0.05 was 
selected before the study to determine statistical differences between groups. 
Serum cytokine analysis.  
 Serum cytokines were quantified as a measure of systemic inflammation. 
The flow-cytometry based fluorescent assay simultaneously measures 31 
cytokines in a single serum sample (BioPlex, Hercules CA). Briefly, fluorescent 
beads conjugated with antibodies against: eotaxin, G-CSF,GM-CSF, IFNγ, IL-1α, 
IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IP-10, 
LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α,  MIP-1β, MIP-2, RANTES, TNFα, VEGF, 
were incubated with a 25ul aliquot of serum overnight at 4°C. The assay was 
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completed according to the manufacturer’s protocol (Millipore, Thousand Oaks 
CA). Samples were analyzed using a BioRad 200 Multiplex Reader (BioRad, 
Hercules CA) and quantified using a standard curve provided.  
D. Results 
Serum ALT and BUN are non-sensitive markers of injury 
 Male and female FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 mice were divided 
into 9 groups with free access to drinking water containing 0, 5, or 2,850ppb TCE 
and a high fat (34% fat) chow containing 0, 10, or 150ug/kg sodium arsenite for 
16 weeks. Food and water intake of the mice was not affected by diet or by dose 
(data not shown). Serum samples collected from mice after 16 weeks of 
treatment were analyzed for ALT and BUN, both classical injury markers. An 
increase in ALT would most likely indicate moderate to severe liver injury, but is 
non-specific for kidney. An increase in BUN would indicate incomplete removal of 
urea nitrogen, a function of the kidney [8]. The analysis revealed no significant 
difference between treatment groups in either of these two markers (Figure 4.2). 
Furthermore, despite the genetic variation present in the F3 population, the ALT 
and BUN remain stable in both control and treated animals. This is likely due to 
the small degree of variation in ALT or BUN between the two parental strains 
FVB/N and CAST/EiJ (phenome.jax.org) as well as the lack of sensitivity of the 
measurement itself [9].   
 91 
Urinary NGAL is a sensitive marker of early renal injury and reveals a 
genetic basis for susceptibility.   
 Historically, ALT and BUN elevations are seen in cases of moderate to 
severe tissue injury and may not reflect minor chronic injury to the kidney that we 
expect in a low dose study. Recently, several clinical markers of early kidney 
injury in humans have been shown to also be predictive in rodents [10]. Of them, 
neutrophil gelatinase-associated lipocalin (NGAL) was found to be the most 
promising marker of acute kidney injury [11, 12]. Here, we collected urine 
samples after 16 weeks of dietary administration of TCE, arsenic, or control diet 
to examine urinary NGAL concentrations. Mice exposed to either high dose 
arsenic alone, or in combination with low or high dose TCE showed a 2 to 7-fold 
increase in urinary NGAL, respectively (Figure 4.3). Interestingly, the analysis 
reveals a striking increase in variation of NGAL concentrations within the groups 
receiving low dose combinations of TCE and arsenic as well as TCE alone. This 
degree of variation was not seen in the control animals, indicating that inherent 
variation in basal NGAL concentrations between individual F3 animals is unlikely 
to explain this increase. Rather, this indicates that the increased NGAL variation 
in response to the treatment is genetically controlled. Such an observation 
suggests a genetic basis for susceptibility to early kidney injury due to TCE and 
arsenic exposure.      
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Serum cytokine analysis indicates elevated NGAL is not due to systemic 
inflammation. 
  Neutrophil gelatinase-associated lipocalin (NGAL) is found in both the 
renal tubule as well as in neutrophils. An increase in serum NGAL can indicate a 
state of inflammation due to its release from neutrophils [13]. To verify that the 
increase in urinary NGAL we observed was not due to a general state of 
increased inflammation, we performed a multiplex assay which quantitatively 
measures 31 different cytokines, chemokines, and adipokines in the serum of the 
control group as well as the highest NGAL response group exposed to both high 
dose TCE and high dose arsenic. The results of all 31 cytokines measured 
showed no significant difference between control and treated mice, confirming 
that our NGAL increase in urine is not due to a systemic increase in inflammation 
(data not shown). 
E. Discussion   
 Several deficiencies have been highlighted in TCE and arsenic research 
including (1) lack of experimental models with which to investigate renal toxicity, 
(2) poor understanding of the linearity of the dose-response relationship at low 
doses, (3) lack of studies examining the effect of nutritional deficiencies, and (4) 
lack of consideration for genetic susceptibility in estimating risks [14]. In the 
present study, we addressed each of these four issues by investigating whether 
the use of an FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 mouse population model could 
reveal a genetic basis for renal toxicity due to environmentally-relevant dose 
mixtures of TCE and inorganic arsenic on a nutritionally-modified background. 
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Here we show data from week 16 of our 52-week study that combinatorial 
exposure to TCE and iAs increases renal injury and that susceptibility to toxicity 
may be genetically controlled.  
 Susceptibility to exposure-associated increases in renal cancer risk has 
been investigated in a limited number of human population studies, with most 
results focus on polymorphic genes in drug metabolism and transport [15, 16]. In 
our F3 mice, we have modeled the population-wide genetic variation in drug 
metabolism and transport, as well as DNA repair capacity by intercrossing the 
two genetically diverse strains of mice, FVB/N and CAST/EiJ, that represent two 
different subspecies of Mus musculus. Urinary NGAL concentrations in the 
control group reveal that there is little effect of genetics or nutrition on the basal 
release of NGAL into urine. However, within groups treated with TCE and/or iAs, 
there was considerable variation in the response to treatment. This within-group 
variation in response can be attributed to the genetic variation captured in the F3 
cross, as each individual mouse represents a unique genetic recombination. 
Because we have held the exposure within each group constant and only varied 
the genetics, this data strongly suggests that the toxicity response is a multigenic 
trait, representing the complex interplay of polymorphic genes derived from the 
two parental strains [17]. 
 We have considerable evidence that diet plays an important role in 
modifying toxicant response through the regulation of gene expression and 
intracellular signaling [18]. One important consideration in the interpretation of 
our data is the gene x diet interaction and how that may be affecting the variation 
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in toxicity response within treatment groups. Dietary factors in this study included 
both modifications in dietary fatty acids as well as reduction of choline and folic 
acid. Uptake and utilization of dietary nutrients such as folic acid are partially 
under genetic control [19] and represent a source of variation in addition to TCE 
and iAs treatment. While adding complexity to our analysis, the gene x diet x 
toxicant interaction will ultimately improve our understanding of how nutrients 
modulate susceptibility to kidney carcinogens, and may lead to the development 
of nutritional intervention strategies in the prevention of disease.  
 The NGAL data also suggests that TCE and iAs may cooperate to 
increase renal toxicity. Environmental metals such as arsenic can act to enhance 
toxicity of organic compounds by targeting common biological pathways [20]. For 
both TCE and iAs, the metabolism and “detoxification” results in bioactivation 
within the kidney to active and more toxic metabolites [21]. Both compounds 
have been shown to interact with protein sulfhydryl groups and increase 
intracellular oxidative stress [21], as well as alter the methylation capacity of 
DNA, leading to epigenetic changes [22] (Figure 4.5). The relative significance of 
this biological overlap remains unexplored pending completion of our 52-week 
study and biochemical evaluation of kidney tissues. However, important for risk 
assessment, individuals exposed to these agents that carry polymorphisms in 
genes that are important in the metabolism and detoxification of these chemicals 
show an increased renal cancer risk, which provides biological plausibility of the 
association in humans [23].    
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 Translation of animal study data to potential clinical and human 
applications has hampered biomedical research of chronic diseases [24]. Here 
we have presented a novel biologically-based animal model which addresses key 
research deficiencies in the toxicological evaluation of carcinogen-induced renal 
toxicity. While traditional risk assessments examine the effect of treatment 
independent of genetics and nutrition, our approach has the combined benefit of 
not only evaluating response to treatment but has the potential to identify the 
genetic varients underlying susceptibility, and biomarkers that predict response 
as well as an understanding of gene-nutrient interactions in the modification of 
toxicity. Consequently, our model has the potential to become a new paradigm in 
the evaluation of chemical risk assessments by improving the clinical translation 
of animal study data.  
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Table 4.1 
Diet Formulations 
Diet Ingredient AIN-93M, Low Fat  
(soybean oil) 
Americanized, High Fat 
(soybean, safflower, and 
coconut oil, lard) 
%kcal Fat 10.2 34.4 
%kcal Protein 13.8 15.1 
%kcal Carbohydrates 76.0 50.6 
Folic Acid 1.5 mg/kg 0.2 mg/kg 
Choline 2.5 g/kg 0.496 g/kg 
Vitamin mix 10 g/kg 11.5 g/kg 
Mineral Mix 35 g/kg 40.35 g/kg 
% Saturated Fat 12.8 23.6 
Omega 6:Omega 3 6.6:1 14.7:1 
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Figure 4.1 
Determination of Environmentally-Relevant Dosage for TCE and iAs 
The determination of environmentally-relevant dosage was based on human exposure data. 
Tables depict the tissue dose-equivalent calculations of TCE (A) and inorganic arsenic (B) in 
both human and mouse for selection of both a low and high dose for use in this study. 
Parameters such as body weight, food intake and water intake were based on previous studies 
in our lab. Dose equivalents for inorganic arsenic do not exceed 2 to 6-fold the exposure found 
in human populations.*[26], #[25] 
A. 
 
 
 
 
 
 
 
 
B. 
 
 
TCE
(drinking water)
Water Concentration 
(ppb = g/L)
Dose Equivalent
(g/kg body wt/day)
Body Weight Water Intake
Mouse - Low 5 ppb 1.25 g/kg/day 0.02kg  (~20g) 5 mL/day
Mouse - High 2,850 ppb 712.5 g/kg/day 0.02kg  (~20g) 5 mL/day
TCE
(drinking water)
Water Concentration
(ppb = g/L)
Dose Equivalent
(g/kg body wt/day)
Body Weight Intake based on 
human blood 
values
Human - Low 42 ppb 1.20 g/kg/day 70kg (~150lbs) 0.017 g /L blood
Human - High 25,000 ppb 714.3 g/kg/day 70kg (~150lbs) Based on water well 
measurements
Arsenic (dietary) Chow Concentration 
(g/kg)
Dose Equivalent
(g/kg body wt/day)
Body Weight Food Intake
Mouse - Low 10 g/kg 2.0 0.02kg  (~20g) 4g/day
Mouse - High 150 g/kg 30 0.02kg  (~20g) 4g/day
Arsenic (dietary) Average Intake        
(g/day)
Dose Equivalent
(g/kg body wt/day)
Body Weight Intake based on 
Consumption
Human - Low 50 g/day 0.71 70kg (~150lbs) *WHO limit: 10ppb 
and 2L/person/day
Human - High 350 g/day 5.0 70kg (~150lbs) #1.7mg/kg in rice and 
200g/person/day
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Figure 4.2 
F3 Population Generation and Dosing Groups 
Female FVB/N-Abcb1a/1b-/- knockout mice and male CAST/EiJ were intercrossed for three 
generations to generate an F3 population of nine hundred FVB/N-Abcb1a/1b-/- x CAST/EiJ F3 
mice (A). Mice were then assigned to one of nine dose groups.(B) Dose groups were created 
using a dose-ratio approach to assess a two-compound mixture at three dose levels (0, low and 
high).  
A. 
 
 
 
 
 
 
 
B. 
Dose Group Dose Ratio 
iAs:TCE 
As 
concentration 
(chow: ug/kg) 
TCE 
concentration 
(water: ppb) 
1 0 : 0 0 0 
2 0 : low 0 5 
3 0 : high 0 2850 
4 low : 0 10 0 
5 low : low 10 5 
6 low : high 10 2850 
7 high : 0 150 0 
8 high: low 150 5 
9 high : high 150 2850 
  
FVB/NJ Abcb1a/1b-/-
F1
F2
CAST/EiJ
Dose
1= low
3= high
52 week Dietary Treatment on Novel “Americanized” Diet
Treatment
N
50F,50M50F,50M50F,50M50F,50M50F,50M50F,50M50F,50M50F,50M50F,50M
TCE:AsTCE:AsTCE:AsTCE:AsTCE:AsTCE:AsTCE:AsTCE:AsTCE:As
0:10:33:13:31:11:33:01:00:0
F3
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Figure 4.3 
Timeline of the 52-week Study and Sample Collections 
Figure shows a time line of the 52-week study design. Nine hundred FVB/N-Abcb1a/1b-/- x 
CAST/EiJ F3 mice were assigned to one of nine dose groups and weaned onto Americanized 
high fat diet at Week 3. All mice were allowed to acclimate to the Americanized diet for 14 days 
before a baseline serum and urine measurement was collected from each animal at Week 6. 
Mice were then switched to Nanopure drinking water containing 0, 5, or 2850ppb TCE and a 
custom chow with the addition of 0, 10 or 150ug sodium arsenite per kilogram diet at Week 7. 
Animals remained on this custom dietary treatment for the duration of the 52 week study. 
Collection dates and samples types collected are depicted in boxes. Highlighted black box 
represents the analysis of urinary NGAL and serum clinical chemistry after 16 weeks on the 
dietary treatments that is shown in this paper. 
 
 
 
 
 
 
 
 
American high fat diet
TCE and Arsenic diets
Week 3:
Mice weaned onto
American Diet
Week 6:
Pre-dosing bleed and 
Metabolic cage urine collection
Week 7:
Begin TCE and arsenic dosing
F3 birth
Week 22:
Serum collection 
and 
Metabolic cage-
urine collection
Week 34:
Serum collection
and 
Metabolic cage-
urine collection
Week 59:
End Study
Metabolic cage-
Urine collection,
Terminal Bleed,
Tissue Harvest
Week 22 samples:
NGAL ELISA
Clinical Chemistry
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Figure 4.4 
Effect of Co-Exposures on Serum Clinical Chemistry 
FVB/N-Abcb1a/1b-/- x CAST F3 mice were given a combinatorial dietary treatment containing a 
dose-ratio of 0, 5 or 2,850ppb TCE (No, Low, High) and 0, 10, 150 ug/kg As (No, Low, High). 
Serum ALT (A) and BUN (B) were measured after 16 weeks of exposure to assess classical 
markers of tissue injury. Data are represented as mean ± standard error from 20-30 animals per 
group. Statistical difference measured by one-way ANOVA, p≤0.05. 
A. 
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Figure 4.5 
Effect of Co-Exposures on Urinary Marker of Kidney Injury 
FVB/N-Abcb1a/1b-/- x CAST F3 mice were given a combinatorial dietary treatment containing a 
dose-ratio of 0, 5 or 2,850ppb TCE (No, Low, High) and 0, 10, 150 ug/kg As (No, Low, High). 
Urinary concentrations of NGAL, neutrophil gelatinase-associated lipocalin, an early marker of 
renal injury, were measured after 16 weeks of exposure. Data are represented in a box and 
whisker plot representing group mean ± standard deviation from 30 animals per group. 
Statistical difference compared to corresponding control group by ANOVA and multiple 
comparisons test (*p≤0.05). 
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Figure 4.6 
Biochemical Interactions of TCE and iAs in Renal Tubule Cells 
Scheme depicts the proposed metabolism and mechanism of action of TCE and iAs in the renal 
epithelial cell. TCE is primarily metabolized within the liver to a glutathione conjugate (DCVG) 
which is transported across the cell membrane further metabolized by a renal-specific enzyme, 
beta-lyase, to a reactive thiol (*), the primary nephrotoxic metabolite of TCE. This reactive thiol 
is thought to interact with protein sulfhydryl groups (SH-) as well as induce oxidative stress 
(ROS). In addition, another metabolite of TCE, trichloroacetic acid (TCA), has been shown to 
alter DNA methylation through an unknown mechanism [21]. iAs is transported into the renal cell 
via an unknown mechanism and is conjugated by glutathione (GSH) and further methylated by 
s-adenosylmethionine (SAM) to a di- and mono- arsenical (DMA,MMA) which can also interact 
with protein SH-groups and induce ROS. The metabolism on iAs depletes the cellulat SAM and 
GSH levels over chronic exposure leading to alterations in DNA methylation and epigenetic 
changes. Further iAs has been shown to inhibit DNA repair through an indirect mechanism 
which can lead to genomic instability if DNA lesions are not repaired before replication [27].  
    
TCE DCVG As III, As V
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MMA
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DNA Methylation Histone Methylation
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Chapter Five: 
DISCUSSION 
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A. Conclusions and perspectives 
 The amount and degree of useful data that can be obtained through 
experimental studies is limited by the available models. Carcinogen risk 
assessments attempt to predict cancer rates and risk for disease in humans 
using mathematical models that are often based upon limited experimental data 
in rodents. They do not adequately incorporate inter-individual variation, the 
possibility of co-exposures, or nutritional deficiencies in the assessment of 
carcinogenicity. This oversight in the evaluation of sensitive and resistant 
populations, limits the accuracy of current risk assessment models.  Thus to 
establish experimental models that accurately capture the human condition, both 
in host susceptibility factors and environmental exposures, holds with it the 
promise to improve not only the data obtained, but our ability to use that data to 
make better risk predictions. 
 The risk assessment of trichloroethylene with regards to kidney cancer 
has been under debate for the past three decades. This is due, in part, to the 
lack of biologically-based models with which to examine TCE-induced renal 
toxicity [1]. In addition, the ban on household use of TCE and improvement in 
occupational standards, has limited our assessment in human population studies 
[2]. It was the goal of the work herein, to evaluate several mechanistic gaps 
identified in the risk assessment of TCE-induced renal carcinogenesis using 
novel genetic approaches to design a best-fit model for our questions. 
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1. Gene mutation signatures of environmental exposures 
 The mutation or inactivation of tumor suppressor genes is considered to 
be one of the main molecular events in the multistep process of carcinogenesis 
[3]. Environmental carcinogens can interact with DNA structure both directly and 
indirectly, with heritable change in DNA sequence constituting mutational effects 
[4]. With the development of improved molecular tools for the evaluation of 
genetic mutations, a push has been made to link specific chemical exposures to 
unique genetic mutation signatures found in tumors [5]. The study of mutational 
spectra of cancer-related tumor suppressor genes can give us clues about 
carcinogen-DNA interactions, functions of gene products and mechanisms of 
carcinogenesis in specific tissues [6]. 
 The link between exposure and mutation is best exemplified by mutations 
found in the TRP53 tumor suppressor gene. Several studies have demonstrated 
a significant correlation between TRP53 mutational spectra and exposure to 
various types of carcinogens. Cigarette smoking has been associated with 
TRP53 mutational hotspots are codons 157, 158, 248, 249, and 273 in lung 
tumors [7]. Similarly, liver tumors in populations co-exposed to aflatoxin B1 
contaminated grain and hepatitis B virus, which are risk factors for hepatocellular 
carcinoma, have the TRP53 AGG to AGT mutation in codon 249 [8, 9]. Further, it 
was shown that in vitro exposure to benzo(a)pyrene, a carcinogen found in 
tobacco smoke, generates strong and selective adduct formation at guanine 
positions in codons 157, 248, and 273 [10]. This type of mutation profiling has 
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been beneficial in cases where we have both human tumors and exposure data, 
which has been a limitation for trichloroethylene. 
 As of October 2010, 388 mutations in the VHL gene were identified in 
sporadic kidney cancers [11]. However, identifying specific exposure “signatures” 
has not been undertaken. This is likely due to several factors including (1) poor 
exposure histories taken at time of surgery, and (2) lack of experimental models 
to confirm disease phenotype. It was the goal of this study to molecularly 
evaluate the P81S mutation using a novel in vitro system to characterize how this 
missense mutation affects the known functions of pVHL and its downstream 
effector molecules.  We have shown that this mutation represents a unique 
phenotype, not previously known to pVHL disease mutants [12]. Furthermore, the 
P81S mutation causes a two-fold hit on tumor suppressor activities of pVHL, first 
by the dysregulation of HIF signaling and secondly by the development of 
apoptosis avoidance. Such a mutation, if not the initiator of tumorigenesis, has 
the potential to cause unchecked proliferation, supporting tumor promotion [13]. 
This will certainly impact the risk assessment of TCE, due to the fact that 
mutated cells need not have access to a tumor promoter in order to stimulate 
proliferation. 
 Over a decade ago, Bruning et al. and Brauch et al. published three 
studies identifying the P81S VHL mutational hotspot in a German population with 
known high occupational exposure to TCE [14, 15, 16]. More recently, molecular 
evaluation of VHL gene in a patient presenting with bilateral RCC with known 
long-term exposure to TCE found a single cytidine deletion mutation which 
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resulted in a frameshift at codon 98 onwards [17]. In each case of exposure the 
resultant mutation identified was located at cytidine residues in exon 1. 
Interestingly, exon 1 contains a known CpG island [18], and further, a 
deamination of a methylated cytidine would result in a C > T transition or apurinic 
site during replication [19]. This suggests that CpG island regions of VHL may be 
more labile to carcinogen insult, an interesting hypothesis that will remain for 
future directions. 
2. Exploiting genetic variation for toxicant susceptibility studies 
 Given the knowledge of human genetic variants and the role they play in 
determining toxicant susceptibility, there have been surprisingly few laboratory 
rodent models used in chemical risk assessment that interrogate genetic 
variation in a manner allowing identification of genes underlying susceptibility. 
Inbred mouse strains are the foundation of mammalian genetics research and 
continue to be a powerful tool in toxicological research [20]. Individuals of a given 
strain are both homozygous and isogenic, and with the sequencing of the mouse 
genome from many inbred strains, the naturally occurring genetic variation that 
drives their phenotypic differences can now be discovered at the gene level [20]. 
Phenotypic differences between mouse lines, such as their toxicity response and 
disease susceptibility, can be used to model human diseases such as cancer 
[21]. As such, in the past five years, the Laboratory Strain Diversity Panel (LSDP) 
has begun to be incorporated into the assessment of susceptible and resistant 
phenotypes in toxicology [22].   
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 The mapping of complex traits, such as toxicant susceptibility, is 
challanging. An analysis of data from the Perlegen 15-strain resequencing 
project (http://www.mouse.perlegen.com/mouse/download.html) revealed that 
most commonly used laboratory mouse strains are largely derived from the Mus 
musculus domesticus subspecied, rather then being mosaics of the three main 
mouse subsspecies(M. m. domesticus, M. m. musculus, and M. m. castaneus) 
[23]. As a consequence, the LSDP that has largely been limited to the classical 
strains has not been maximized for genetic diversity, which limits association 
studies [24]. The uncommonly used wild-derived strains can increase the amount 
of variation. A more recent resource that is coming to fruition is the Collaborative 
Cross (CC), which was designed to be a genetic reference mouse population that 
controls for the randomization of a large amount of genetic variation by the 
structured breeding of wild-derived strains with classical strains. The CC is 
predicted to contain more single nucleotide polymorphisms than the human 
population [25, 26, 27]. Once this resource becomes available it will undoubtedly 
have a profound impact on human health and disease research. 
 Single strain risk assessment studies are limited in the information they 
can provide, and as such, human disease risk may be underestimated for 
susceptible individuals. For the work presented here, the CC resource was not 
available, but we were able to use what is known about the relative contribution 
of wild-derived mouse strain genetics to maximize the efficacy of our mapping 
population of renal toxicity. To design our mouse population, we had to make 
predictions about toxicity mechanisms using those factors we hypothesized 
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would play a role in TCE and arsenic co-carcinogenesis. We incorporated a 
knockout mouse to mimic human excretion of inorganic arsenic, altered the 
dietary factors to increase tissue dose and susceptibility, and properly chose a 
wild-derived strain counterpart, CAST/EiJ, to maximize the genetic variation in 
our F3 population. We were able to show for the first time in a mouse model, that 
renal toxicity due to environmental co-exposures to TCE is dependent on 
genetically-determined factors. Moreover, we now have the ability to identify the 
genetic factors underlying susceptibility, discover biomarkers that predict 
response, and to investigate the gene-nutrient interactions in the modification of 
toxicity.  Such an approach to chemical risk assessments is likely to reveal data 
that is more useful for translational studies, as well as aid the refinement of 
animal use in toxicological studies, as several phenotypes may be observed in 
the same study facilitating collaborations.  
3. Environmentally-relevant doses and diets in toxicological studies 
 It is becoming increasingly obvious to the toxicology community that a 
great knowledge gap exists in our understanding of how environmental toxicants 
behave and interact at very low exposures. The National Institute of 
Environmental Health Sciences (NIEHS) along with other health agencies are 
leading a paradigm shift to investigate how such low doses impact human health 
and disease [28]. By definition, to achieve an environmentally-relevant dose, the 
dose-equivalents in a rodent study should be based on the internal concentration 
of the toxicant or its metabolites as measured in urine or serum of humans [28]. 
Although this dose will most likely represent an actual range for a typical human 
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exposure, it remains limited by the availability of actual human measurements. 
Recent work on endocrine-disrupters such as Bisphenol A suggested that high 
doses may not be appropriate to predict the safety of low doses with hormonally 
active or modulating compounds [29]. This becomes especially important when 
considering mixtures, nutrient-gene interactions, and genetic variation in 
chemical metabolism and transport. 
 There is a paucity of publications discussing the use and results of 
environmentally-relevant doses for both inorganic arsenic and TCE. The 
challenge with using very low doses of trichloroethylene and inorganic arsenic 
has been the inherent species differences in metabolism and transport between 
humans and rodents, and the lack of methodology to quantify internal dosimetry 
[30]. We have recently shown that there is a strong strain-dependent difference 
in the metabolism of TCE [31], supporting the need for increased genetic 
variation in a mouse study population to mimic human populations. In the present 
study, a drug transporter knockout mouse was used to increase the 
sequestration of arsenic metabolites in the kidney [32, 33]. We were able to use 
a toxicogenomic approach to show that environmentally-relevant doses of 
inorganic arsenic produce a characteristic gene expression signature, even after 
only 10 weeks of exposure. We have also shown that environmentally-relevant 
dose mixtures of inorganic arsenic and TCE result in significant renal injury, and 
that laboratory diet composition likely plays a role in enhancing toxicity.  
 Dietary deficiency in micronutrients as well as an imbalance in dietary fatty 
acids can increase susceptibility to environmental toxicants [34]. This becomes 
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especially true when dietary co-factors are needed for metabolism and 
detoxification [35]. As such, nutritionally deficient populations represent a unique 
and vulnerable subset of the population and are likely to be at increased risk for 
adverse health outcomes [36]. In the U.S., obesity and poor dietary habits likely 
puts the majority of American adults and children into this population [37]. It 
becomes important when designing best-fit models for toxicological risk 
assessment studies, to not rely on existing data, but rather to tailor models that 
can best answer the question(s) at hand, taking under consideration: (1) Who is 
most at risk? (2) Is the dose relevant to human exposure? and (3) Are there any 
dietary factors that can be identified using epidemiological and animal data? 
B.  Challenges and limitations 
1. Study limitations 
 Carcinogenesis studies require animal models that best describe the 
human condition, both in the underlying tumor suppressor gene mutations and 
the mechanism of cellular dysregulation which occurs at each step from initiation 
through tumor progression [3]. In the study of the P81S mutation, the lack of a 
rodent model of RCC hindered our complete assessment of the relevance of the 
mutation in the development of tumors [38]. Nonetheless, this limitation showed 
the need to elucidate the yet undescribed functions of pVHL in order to fully 
develop an appropriate model. While gene expression studies comparing the 
P81S mutant teratomas to those containing wild-type VHL protein suggest that 
mitochondrial biogenesis may be the mechanism of apoptotic avoidance, the 
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quantification of such an increase as well as further molecular studies are 
required to prove such a mechanism. 
 In Aim 2, we studied the dietary influence on kidney gene expression with 
environmentally-relevant doses of inorganic arsenic. While transcriptome 
analysis is useful in determining a dietary effect on tissue response, the gene 
signatures and pathway analysis itself provides little information for 
understanding the underlying mechanism of toxicity. Thus it is important to make 
a connection between differentially expressed genes and phenotypic markers of 
toxicity, to understand how sets of genes and their products work together in 
generating adverse health outcomes [39]. In addition, a lack of pharmacokinetic 
data and tissue metabolite quantification of inorganic arsenic on both dietary 
regimens prevents us from knowing if the diets altered the absorption of arsenic 
or modified its metabolism in situ, and thus, the reason for altered kidney 
response signatures.  
 In our animal model of co-carcinogenesis of TCE and arsenic, we only 
examined a snap-shot in time at sixteen weeks after exposure. While we were 
successfully able to observe a marker of kidney toxicity, it is not necessarily a 
marker of frank carcinoma. It is generally believed that the presence of 
nephrotoxicity is not directly linked to carcinogenesis, but only suggests target 
tissue susceptibility [40]. Furthermore, without integration of genomic data from 
each of the study animals, it is not possible to draw specific conclusions as to the 
genetic interactions underlying variation in response, whether due to a gene x 
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toxicant or a gene x nutrient x toxicant interactions. This data will be required for 
the determination of kidney injury susceptibility in our mouse population model.  
2. Limitations in co-carcinogenesis studies 
 A few of the current limitations are centered around two main areas: (1) 
the need for reliable quantification data of exposures in humans, and (2) 
integration of susceptibility into our laboratory animal models [41].  
2.1 Overcoming exposure-data deficits 
 Exposure data is required for determining and characterizing risk, as well 
as for guiding the selection of environmentally-relevant doses in animal studies 
[42, 43]. Human exposure data for TCE and inorganic arsenic thus far have 
mainly been limited by the sensitivity of the methodology for quantification. For 
inorganic arsenic, there is a clear understanding of which global populations 
have been exposed through water and food sources [44]. The challenge is that 
exposure estimates have relied heavily on toenail or urinary concentrations of 
total arsenic [45]. These measurements are not accurate assessments of internal 
dose, nor do they provide information required to estimate tissue dose. Recently, 
the use of atomic absorption methodologies have improved the sensitivity of such 
measurements, enabling quantification of methylated metabolites of arsenic, 
which can indicate inter-individual differences in arsenic metabolism [46]. In the 
U.S., the exposure to arsenic is likely to be far lower than endemic areas of the 
world which needs to be taken into consideration in estimating exposure to 
mixtures.  
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 Historical studies of TCE-associated kidney cancer have relied primarily 
on questionnaire data and estimates of occupational exposure based on 
workplace variables that have been characterized as low, medium or highly 
exposed [14]. Unfortunately, these assessments often neglect personal 
information such as body mass index and other risk factors associated with renal 
cancer such as smoking [15]. This has made exposure-association studies 
challenging despite the number of archived tumor tissues available. Gene 
mutation signatures may not be a realistic goal for determination of exposure, 
especially if the exposure is in a mixture at very low levels. Instead, collection of 
biological fluids such as urine and serum at time of tumor harvest may provide 
insight into exposure in the future. While highly sensitive mass spectrometry 
methods to quantify chemicals in a single drop of blood are currently under 
evaluation and validation, the availability of these fluids in the future may aid in 
exposure assessment [47]. Thus, it remains that there is a great need to discover 
biomarkers of exposure that have a strong correlation to tissue dosimetry and 
disease outcome for prediction of human health risk. 
2.2 Chemical mixture evaluations require population-level models 
 Environmental exposures are typically complex mixtures of compounds 
often seen at ambient levels. The chemicals in mixtures are often poorly 
characterized, the mixture ratios may vary by location, exposure data is uncertain 
and the toxicological data may be limited [48]. This makes the implementation of 
methodology a challenge for estimating health risks. Under the current mixture 
assessment guidelines, several different methods are discussed to estimate the 
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risk of “common mechanism” chemicals with different potencies in a combined 
exposure [49]. These are the hazard index (HI), toxicity equivalence factor (TEF), 
and combined margin of exposure (MOET) procedures, as well as the point of 
departure index (PODI) and cumulative risk index (CRI) methods [50]. At a 
minimum, each of these methods requires the availability of in vivo toxicology 
data. Therefore, the in vivo animal mixture study design and its ability to 
communicate possible risks through mechanistic approaches are at the 
foundation of these decisions. This emphasizes the importance of animal models 
that can capture the representative population in both biology and susceptibility, 
and further drives the need for rodent population-level models in toxicological 
studies. 
C. Future directions 
 Kidney cancer rates continue to rise in the U.S. and while risk factors have 
been identified, they do not provide a clear mechanistic view of the development 
of the disease [51]. As highlighted in the work herein, the improvement of 
laboratory models that capture both human biology and exposure may greatly 
impact the type and usefulness of the data obtained. In the study of the 
exposure-associated VHL tumor suppressor gene mutation, it is clear that not all 
functions of pVHL and/or downstream effectors have been completely described 
to date, suggesting that studies should then be directed at continuing to fill this 
knowledge gap. As well, future work may examine the possible structural basis of 
susceptibility of VHL to carcinogens that act by altering epigenetic marks. Finally, 
there is a strong need for an animal model of RCC with which to examine 
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disease progression and etiology. Without such a model, many questions will go 
unanswered. 
 The potential of genetically defined inbred mouse-derived populations as a 
surrogate for studying genetic variation in the human population is only at its 
infancy in toxicological studies. It is anticipated that the results from the 
population-level study of TCE and arsenic co-carcinogenesis will identify genes 
responsible for susceptibility to kidney toxicity, as well as identify biomarkers 
associated with susceptibility for translation into human populations. Further 
integration of genomic sequencing data, biochemical and histopathological 
evaluation of kidney tissues, NMR analysis of urine and finally QTL mapping of 
toxicity phenotypes will all be required to accomplish this goal. 
D. Summary  
 In summary, in vitro and in vivo models that best describe human biology 
are strongly needed in toxicological evaluations if the information gained will be 
of any use to risk assessment decisions. For many years, toxicologists have 
relied on a “single exposure, single strain” approach that has led to a lack of 
consideration of the influence of genetics, mixtures and nutrition on cumulative 
risk assessments. Our approach to designing a population-based mouse model 
has the combined benefit of not only evaluating response to treatment but also 
the potential to identify the genetics underlying susceptibility, biomarkers that 
predict response as well as an understanding of gene-nutrient interactions in the 
modification of toxicity. As such, this type of model has the potential to become a 
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new paradigm in the evaluation of chemical risk assessments by improving the 
clinical translation of animal study data. 
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